var title_f7_12_7360="Horizontal neck lines";
var content_f7_12_7360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69540&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Horizontal neck lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Horizontal bands are present on the upper neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7360=[""].join("\n");
var outline_f7_12_7360=null;
var title_f7_12_7361="Gallamine triethiodide: International drug information";
var content_f7_12_7361=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gallamine triethiodide: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4089036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Flaxedil (AR, AU, GB, HR, NL);",
"     </li>",
"     <li>",
"      Flaxedyl (HU);",
"     </li>",
"     <li>",
"      Galaflax (AR);",
"     </li>",
"     <li>",
"      Miowas G (ES);",
"     </li>",
"     <li>",
"      Relaxan (DK)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F4089037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Skeletal Muscle Relaxant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F4089038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produce skeletal muscle relaxation during surgery after general anesthesia has been induced",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F4089040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: 1 mg/kg then repeat dose of 0.5-1 mg/kg in 50-60 minutes for prolonged procedures; maximum single dose: 80 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4089041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: 20 mg/mL (10 mL)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10451 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-042A3B073A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7361=[""].join("\n");
var outline_f7_12_7361=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089036\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089037\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089038\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089040\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821083\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4089041\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_12_7362="Patient information: Anterior cruciate ligament tear (The Basics)";
var content_f7_12_7362=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15841\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/21/10578\">",
"         Front view of the knee",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/48/1797\">",
"         Patient information: Anterior cruciate ligament injury (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anterior cruciate ligament tear (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anterior-cruciate-ligament-tear-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25046850\">",
"      <span class=\"h1\">",
"       What is an anterior cruciate ligament tear?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An anterior cruciate ligament tear is a type of knee injury. This injury usually causes swelling and pain in the knee. It also makes the knee feel unstable, or like it is &ldquo;giving out.&rdquo; &nbsp;",
"     </p>",
"     <p>",
"      A ligament is a tough band of tissue that connects one bone to another. The anterior cruciate ligament, also called the &ldquo;ACL,&rdquo; connects the thigh bone to the shin bone (",
"      <a class=\"graphic graphic_figure graphicRef77293 \" href=\"UTD.htm?10/21/10578\">",
"       figure 1",
"      </a>",
"      ). It works with another ligament to keep the knee from moving too far forward or backward.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25046857\">",
"      <span class=\"h1\">",
"       What are the symptoms of an ACL tear?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When people have an ACL tear, they often say they heard a &ldquo;pop&rdquo; when the injury happened. This injury tends to happen when people are playing sports that involve quick changes in direction, such as basketball or soccer. They can also happen when a person slows down suddenly while changing direction. &nbsp;",
"     </p>",
"     <p>",
"      Within a few hours of an ACL injury, the knee usually swells. It can also feel unstable or wobbly, like it can&rsquo;t hold your weight. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25046864\">",
"      <span class=\"h1\">",
"       Is there a test to check for an ACL tear?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse thinks you might have an ACL tear, he or she can order an imaging test called an MRI. This test creates a picture of the inside of your knee. But an MRI is not always needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25046871\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Some people feel better if they do certain exercises. Ask your doctor or nurse which exercises might help you feel better. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25046878\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you have the symptoms described above or if you think you might have an ACL injury.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25046885\">",
"      <span class=\"h1\">",
"       How are ACL tears treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Everyone with an ACL tear has to do special exercises for a while after their injury. These exercises are called &ldquo;rehabilitation,&rdquo; or &ldquo;rehab.&rdquo; They help you strengthen your knee and get back the ability to move it around.",
"     </p>",
"     <p>",
"      After the swelling and pain of the injury get better, some people have surgery to rebuild the torn ACL. For this surgery, doctors remove and replace the damaged ACL with a strip of tissue taken from another part of the leg. (Sometimes the tissue used for repair comes from another person&rsquo;s leg.) After surgery, people must do a lot more rehab to make sure the rebuilt ACL works well. &nbsp;",
"     </p>",
"     <p>",
"      But surgery is not always needed. Some people with a torn ACL do not have surgery and instead do more rehab work.",
"     </p>",
"     <p>",
"      The decision about whether to have surgery depends on a lot of things, including:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        How unstable your knee feels even after doing some rehab",
"       </li>",
"       <li>",
"        How severe your injury is",
"       </li>",
"       <li>",
"        What kinds of physical activity you do. (If you are very active or do a lot of things that involve twisting or turning your knee, surgery might be a good idea.)",
"       </li>",
"       <li>",
"        How old you are",
"       </li>",
"       <li>",
"        Whether you have other health problems",
"       </li>",
"       <li>",
"        Whether you are willing to do a lot of rehab after surgery to make sure the repairs work well",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25046892\">",
"      <span class=\"h1\">",
"       How do I decide whether to have surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You and your doctor will work together to decide if surgery is right for you. As you talk about surgery, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        How will my rehab be different if I have surgery or do not have surgery?",
"       </li>",
"       <li>",
"        What are the risks of surgery?",
"       </li>",
"       <li>",
"        What are the risks of not having surgery?",
"       </li>",
"       <li>",
"        How well will my knee work if I have surgery?",
"       </li>",
"       <li>",
"        Will I be able to keep doing my favorite physical activities if I do not have the surgery?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25046899\">",
"      <span class=\"h1\">",
"       Can ACL injuries be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting an ACL injury by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Being physically active and building strong leg muscles",
"       </li>",
"       <li>",
"        Doing exercises that make the muscles that support the knee strong and flexible",
"       </li>",
"       <li>",
"        Learning how to move so there is less stress on the knee during sports",
"       </li>",
"       <li>",
"        Talking to a fitness expert about how to move and position your body, especially during physical activity",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Along with the steps listed above, it might also help to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Do strength training, meaning that you work with weights or your own body weight to build muscle",
"       </li>",
"       <li>",
"        Work on your balance, for example by standing on one foot",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25047037\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1797?source=see_link\">",
"       Patient information: Anterior cruciate ligament injury (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/12/7362?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15841 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7362=[""].join("\n");
var outline_f7_12_7362=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046850\">",
"      What is an anterior cruciate ligament tear?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046857\">",
"      What are the symptoms of an ACL tear?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046864\">",
"      Is there a test to check for an ACL tear?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046871\">",
"      Is there anything I can do on my own to feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046878\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046885\">",
"      How are ACL tears treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046892\">",
"      How do I decide whether to have surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25046899\">",
"      Can ACL injuries be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25047037\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15841\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/21/10578\">",
"      Front view of the knee",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/48/1797?source=related_link\">",
"      Patient information: Anterior cruciate ligament injury (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_12_7363="Junctional EB Herlitz 3";
var content_f7_12_7363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa type Herlitz (JEB-H)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blisters, crusted erosions, and large denuded areas in junctional EB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7363=[""].join("\n");
var outline_f7_12_7363=null;
var title_f7_12_7364="Bunny lines";
var content_f7_12_7364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52791%7EDERM%2F64576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52791%7EDERM%2F64576&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    \"Bunny lines\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 327px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFHAfcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDnIc8VoQdOaowYALN0pZ75Il+X5m7Yrxz2LmoCobHelafYvOM+lcldaxKG4Yr9BzVQ6i0kmZJJNvoDihplJnZ/aJM8nr71atJ1DfM6j6c1wzasEHCOw9zUx8QOqqIgI8jjHFJRZXMj0eKcH7uB/tGrcU7EAbwfcYArzJNbuiysWYr0IU9Ksr4leMlVkkB6YZeadmJtHpXmRgYY8j1NNF6irgP19FJNcDb66kx+eSWTHUf/AFq1YNVi3b4txQfxDGPzoaY0dWt3A2C+f+BcU+KZNx/eLg9ApFYdtqttcfdfce/Na0LgqDuHPsKQF9SN3Mh3dccVY3oR8rDPcLzVCL7u7gr3yeCKclxg7QnB6HHSmtBbllpBgnJLD15qRJmZcgfL6EVSkkXhWHI7g1PHjbkKT7k00PoWJJCF3KoI789KbYyboSAy5VzwPrQVOzkAfhUNvuRpdmB83ORnsKGtQT0NMvyCp+b16Uw5D7WUk9sHFMDOSvlDdjtt5NK0h/i6g9MH+tMExXG4DknnNKCEO0k8j0pjFVkyvzJ1z/SlZlzlT9OM0yrkM8W6RTuxg9M1YRtiZHUVG4DjPFINoUAckDGalqw73RZMm4YNOHJH61VVmODU8T4PTH1NG4FmP647U9Sdoz9RiolcAGhpMHI9O1ULUt713jHfrg1MXCKwzuAbt+lUQ6grtwPUkVIZSRnbkEfLnv71SYnEldxnEo5PTB6DFMaUMexXORg96hZnZ97ZLEYYg80LIoUIpAPTmkx2sO3cFj9MUgkAzg8/Sonl6AdKhLhnPvzSYcpOzBzwoznrTGlDEADHqaYGCZA/KoWkHQcc9aljsTNjpkkeuKhZmcMBjHvSSOeOfzNQbjyenOfrTGh5Uqp7nrg1Gx2oT3xikaR+cfhTgCI+SMZz60BcgG95Bg8dOafvZcZHfB7Ur4K/IPm7VGZMdTkdxQF7llHXdxnGfvGkLMXChQNo4I71E65wB8p9qBI0anJO4e+PxpkNk+4blGee5xxTJJkHEgKt2I4NVWnCqSWVM9+cVlXGoFSS7q/p2FFybGy0+0Hc2VPUMetZ95eFFbYxZRzjOcCsHUddigUtKIynQ/Nkf/rrBuPE5EbBUj2ZyuWz/KhK5LdjqxqkafeaQ56jGQPeq9zr0EbACZDx/FxxXC3XiF3wFiVWHUbjjFYt1rE1xL+9y2T8qYyPwHemoMlyR3954ls4ckpuU/xBSRWHqHiaK5GIC4f0JIA+pFcjNcqpYtNsY8BV6j8O1DTp8gF4Cu3a2IM4/Mdfy+taKBm5mnc6qJFCyrgZ+by0Az7fSqcusOCsUJSMe2ckVjXQka5WOJydxwN5CE/UDpV2OwureBZLmNJI88BZBz+IPNX7MXtOxaklgEQkmunMmehP/wBamtPG8IaAK0g7Fi278MVRitJ5ZGaG3RV/2hkD8604LDUCylJGVgMfux2qXyouMZsq+ZLIAXYQkdQFwP8AGolkmGVgzjvtB5roYtAuJvmk8xm/2zwatQaBMpwyjA9qly8i1T8zmYnvifmLbR0G7AqwZ7jzSw3K/H3QT+VdnDo0YUAQxk4yakOk5BG0IfpxU3ZXKjjA127BjIzH6inzSzhQSXZvRufyrpH0tFJE0efQis+40yMMcltvbBxRcVjETUr6B/kkA925oqW+03P+rbcPQ0U7oXKzoZ7uOFcyZOOgFYl1qeWYRADPc1HeXhkYjcAp7VRG4bm+Q/71Ql3JuMluWcnc/wCXFQfaPLJO85pJBuYnyyx/IVWdCc7gwUegrVJEtsum7z98sc9z3pftG1gfKJTPIqjGCnQ5T3FL9oETDACkHJB6flT5Bc5otfIU/co8fqQeKYZlZwzM54yCMc/WqbXRJydhz0AxTNu0gglGPT0FPkF7Q1be7G7DFhj+IDgVpxXzeWADG8Y9sGubDtG25mRiR2zViOZ2lTyiNx4+9g5+tJ0xqodHBqkLtktskHQg4IrZtPELxIBt84AdMDP5VxM1w6sFuVIzyGIBP4Gm2968DERS/KDxnnNR7Mr2h6Va64LgjMoQA/dAwR7Yrat77emFkKr6DvXlX21JIwWmwSfutxg1oWmpP5e6ObnpyDn8s1DpGntT1S2vNoxEoBx941opcOSCz5BHXtXlun6zLHMVebKkcHJ/LmugsNSWZ9ssp3ddpPBH51NmirpnbLOAcqdzDoS3FSW0rG5fv8o5z9awLS9iZcbo9g461eguV+15WVANnYe9IDbLkknqfwFReaWcHhfqP61XW4QqBvBOc4zmpQQ55DL9apDWhZXzAR9zjtgc0bj1UD9CKjVQUznkdjQTsJ6D0A6U9BolTnO4D1qKSRVxgd+g7UnnI33zlu9G1W24JYj16VLKXmCTgyLuIGOwFWS/IPr6VVVAHJz1PAAp8TkLjoaS0Hp0LsfIUHGO9OAAJweKrI7BTjk4qUN90Y2jHaquBN94ADOKIDwRv245XjPPoaF+4RnAPTjvTQfnIOBnjkZpgTISS4zznr0FQvjOQPmzyc0MzMuM9D0x1qszb3GDQ2CRMDj7xHNMckfX1qOU+WTxgk00OzA9yOpNS2Ow5nOKiQqG780iE7SD+BzURkyGAoYvIklZgRgg+1RsxVfnPOccUincwJyPTPeo7ltzDpn86EPyFOd4yePWlZmKgAEoO9QO5IHf6U+IYG8gY9zQwZMr/PwAB0zT5SvG4dBgN0qvkAZb1zioLp90ZTcQD6GnqZlkyRqBvJBGTnNZmo6jDsO1mLjp6Gs3U7h4IcRz8k4A2/oTXPahqfkqZZMYUZLIuQfqSaFdit1L95qlyFAlMewEkKrc/nisS81eaZW8nEYHJctn9TgDFYWpapd3IJbMcbH5RnlhXPXU7FmEr5C8YB4Jq4wvuZyl2NS6vROGkuH3qvCKvG7368frVO0v3jkLiVkznLE4wPTP+FZxdWXDuF3d8ZP4Cn2czQSOLYIzFT87oCQPXnhTWyiZSlYvanqhuVjjiUbVHL7QgP5csfc1TH2Xym82Zw/X5BlQP559v5VQlvVZ3QfOW+8epJqKNZXyACq5+pq7JbmavLRGh9qSVBGsIjhU5UjhicY5J6frTIEdgyKiszNncufyzVzS9GmunBIbYO9d1o+i2luAZBl6hz7GipxWstTirbRNQdgwicHtxit+z8MXTbS21B9cmu7H2dVVFHznpxxVqODAB6r64qHZmsZWWisc9pvhuNFBkJdvTtW9HYwQRhdnHsKth1RP3a4I9apvNlsNuxnqKV1HYWstxz7JIwqrtAPSljVV+Ur+dNkkAwVAAHTFQvOWPHX0FS5FqJMUjXn7p61GJVk7dKgaXd8rA56daiZ9hOMg+9TcrlLVxtK4Cg1mT26NnjApZp37d6VpCseWpom1jNktEJxgUVMzhuuKKYm2edvy/wAgOPU1KkTs3yE1cht97YIxW1p9hH/GvXpRzEKK6mXbafJIMFuT6CrZ0SQjAG4966mys4kGQBkVdVMchRUl+h57LoroxBjx79KpTaVKmTs3/hXqLWqTr84XNVW0ZdzYbg9qpNisnueWSWpRf3kWD7iqbAAkKrL6GvWZPDyy/fx9cVl3vhbG4KoKnvVqbW6JcIvqcAiujL58YKEYyQQPzpCyYOyPnP3ic4rqLjQpoODyPQjNZF9p6KBtDBx1GOKtVV1M/YvoZonmVSrgsoPAIyP/AK1WEC3MeYYirr1IOaJJTGq7UJmHV935VVJmacneIiep9apNPYhxlHcsm5kX/XR/KOOnFSBiJPNhmTjqgbk/hVB5JURlXaTjBIPB/A1RaQMepRzVWJvY6ttRknjVEJDgbWUnG78+9Ja6qYp2S53BcZXJOQawI2Ypt3fOBxnJDCpULGLzh86A4KEZFQ4FRnY7u0105X53ERGCwOa2bLWHaQN5m9McBmNeXi/QbRGHVR6mtOx1Aq3DkE9x61jOmzeE0z2HTtVSQfKAzDsK1bW/R2AZsP0C15ZYah5Zjk83npvB/nXT2upOdr8owHzMnGffistUbLU76OcElm+XI4I5xUsnlk7wykjrgf0Nc9YXsbhHklQhhwQM5NakbKc4IJ68Ci4WLYXqwznORjvTl3tgsRgc8jFRI5X7uAPQ1INzAkjHPQGhjuKc7TuAGTnjFNRkC4HJHXmhwMYJIx71EAyk8jafWobGncnikHrkY6Vaj2tGcNgD86osqgqMgk4wAasqwXBbOemKaKLRcbflbkdOelNCnzFx9736VHhSWJ6nnA/lUhJ8shgSfYdKtDJSVXdvbLDsOg9qq7/nyenoKW43RsqMwyB1HNMPQHjFO/QLWI5GUDLZ649aZG/XCk45xU4KleBxmqskmBhBwDzjvUhe+gjltpZOBiogwHoRR5524CksfvfSo1O8kZHsKlgWg64zngdR6VDI43ZGCOaawOCSOR71CWDOcDoPwqiRd/PTHvTWlO0DOMCmeYQDyMGozIo5X164osNsBK8kLeYx3KduQecf5xVe4l/dFSxUDuxwSPasw3bx38saucYVgOOeo/pWRq928xk8+UpEg52+vpn/AD1prUiRW17VgJ/LtiWKgn6H1P61ydxqMrI32lyXGdqk8D0OPWnT3ct0zNGg8tTxnjA/z2rD1CXDEhkbd1I6D2rWMTKUhz3bpnn5z1J6AGqspWQkxghUXJZz1PtUUkjdeOe9RPI0gC4O0c4NbJJGDbbCWUl8kg4Pp1qNgzgCRsjsBU6KmMsAWHSm4AO7GAKL9gUerHW8PIwmB7Cul0nTFcq7gfnWTbXMSgfKSexrTgv5ZFKxREY4zUNNl3SOsgSO1Rcfdx26Vbj1OLzDEgG7GSc9K4lLm9mhmMTR7Yxk5bpV2CxvLWFHklhdpV35BPGfWj2ctyVUje1zt11CNZI1YANjOasya2qwsrGMKvOelebJd3Ykefqn3fvelV7nULieIGQHyAc5/vHsKnkkaKUT0I6u1zChRhGXHy8849atRXSIoy5Y9Oa82g1ho5C0yMjEYAx0FX11xdm484/WpaexorWud0bkGQDcOe2elNmnUA4ba2e1cda6moZppHKseg9Ksf2kJBsR8yN0PYUrDTOmLLhWLE5HWojICxBYt71nwzL5CqHztGM+tOWdFOM8VIzQZ0wRwDVSaQtxnioJbhAD61V+0MwJTBoFcmc9qKpS3BCjNFBDYy0tucmtWPCgcVVTAHWp4nBGDSGi7FPgjFX4JQ3BrJRcc8GrcDjHQ5pbF6GpEUDc1aAGQQQay4wzkcYq5GdvWhMTRfBXPPSmZVzgEVAzkAFm4qNiS3y0+Zk8pLc28TDDBWrLutLt5DzEoz3qzDN/pc1sTltocc9j/wDqq3byRyxHzANwOCO4NFxWscneeGLWQMVBVu2Kwrnwm2SATXpJRf4etK9qHXLD5fWqQnJo8euvDs0WQhyBWJd6fIrYZSCK9ijs4Z/MwNzZYqR2IJqoNNtru0eQRD59wxtxjtVqTRDae6PHjFJG3BpxuZUAGMdtw6/j613OpeHvNhilt4+H4/z+VczfaZNB9+JgucZxxWiqNbkunGS0M2KRHPA2n+IetWLaRoZMfrUZt8H7vNOxkAHsOD3FVzJi5HE1rG78uT94AUY9/Wur0y98tVAY+X19TmuEi9CR/Q1qWk7Q7ATkd8HnFYzjc2hI9F027AcrGqCKTt1Ge/FdDYTmPAZjs7EHgf59a86028hMhDSFVxlf/r109leyJE7rIrYx8hOC30rFqxre53UFzjA2rj1zVoPlcqBu9h0rm7C6R4wVQjIzWxb3BYHJ4H50rktFxpeu0fU96ryvvPJ47DOMUksybeMfSs+Vg8nyyAbuNpqJMqKNGAovI3Zxgc5/pV2M5B389gDVCAFVGAwx0xVpJVUHd948e5pI03LocIBgADA9yakycAqxz6nIxVGKY5yTwRwcc1OrRjOGLNjOPetEx2Hzbgc7lweOMc/Wq5bBJY59DjFTT7lwZGRR3xVdwWXO8MWHp059atgth29VXGcEjtVaYL1JOT2qQnZHyocZ+91qu7hSQVCjtjFQ2CG7ymcNx0x3ApGwJN6jnGMjimM2fmUbc9CR1qOVsKWY7s9QKLiZN5ihcc5I654phZCcMQD69qgL7eVb5ccr6VGJPOGAQB2z3oT6E+Y26mKISoHHb2rLmvHyykqSRuwOlW7txAhbBxXJ6pcv5ybZSqsrAjuO/wDSnbULjZbsveoxbYGiJK+vPHNYWtXz3B+yRkqvUt/ntUcs5jgRwznEa47cAdM1jzTvu3E7ec8HBrSKM5NhdS7gQG3Y4HGBWbJyzBgOOmKmkcupyAo9B2qszqh6jNaLQzcbjGBI5psxEa0yWVn4jFT2WnySuGkBwaoT0KqCWc4Rfxq39gaON3uCQMd62RFDZhRgZrJ1fUVmOwdquKMZz0Na0FjFp8TkZcrk1m3WsP5bQWihA4wxrHluZzGqDhRVZXcMASetaJMxc0a0EzrLGGYBFO4jP3jWhc+ILqaEW8YA/g3jsKzdc/487ZmtJLeQLjeUKh/f3rHjeQE7XOTT5eqJU4s6p9QRYY45WYon8I71El6Z5DK+FjU/JH2+prnkFxksvzY5oa6Y8OCKnlexXMjpm1WMDMgV3xwMZpYhbPH5k7HzTztUYC1zCuGGUPzetSCab7jOdh96OWxXOzZYyyTCO2JfvVuKa5siTLEeR1qjp+p/2cP3USszD7x61P8AaL3VWwcKP0qHFNGkKjT7mpHr8aKMkknjFaNpqAmUlnA9BWUdAgSEHzAZepPvVaOwlRsKxBH61lKC6G0Zt7nTNcFwRkE+1RrIRwOSaw1mlt2xNkf1rQhlLIGBrNormJ3Jb7xxRULsX+tFArmp5vPNKk+GqnvyOaQPzUFo2YJNx4atC3lKMM8isK2LZ4rSgLEj1qbjNbzj1HFE9wzQEQ8SDkfWqok+bDEZHapPtcKnH8XpS1HdEunX32yJlkGx1O11PY1ajmZG8tyP9lvWuc1QqxFzaSiGdRz6MPesm48XxwxmG8TbIO68j61aV9iG7bnT627QSR38JzJBw6j+JD1/LrU0esW2xLyBg1u4/eY6j3rzfUPGEkiFY+e2fUe9cwuo3KNJ5MrIjnlQeK1jSkzKdSK6nvp1exUKzTptPJ57VBe+J9JjXatwCMdM968EN3Ls5nPPbNNWcA5Lk1fsH3I9tE9R0/xhaQ27AvtdWkXp1ycik0fxnawR3UNw2R5jFTjqCc15NJOAxwvfNJFJLLIFjUszHAAFaewMnWSPUYfF1p9njTkbJDge3NOudetLiOFWKbCTxXmV1FdWUnl3dvLC/XbIpU/rSJOeOvWj2XZgqyZ2VxFBcTTPbsqqvHXrVIW+WOCKxYZnDna+M+9Tw3csbHuKh02jaFVM1TbbTxx9KdG5jwG5HtVFdRycOuKuQywuo+cH+lS0+pqrPY0I5SpBG3cOQT39q27C8xsZANwH3Qa5kyAD5TkfWpre6KY28D0rJq5oj0nS71WfduKu/wDCBit+yuHVCCd3fPpXmNjqbeerSMWPtXU6TqTSbd5Ax0FZNFWOtllY/MMYxTbZc/O4wfbtVa2fzSGY/L6Z61eWRQhxgY4xUtAn0L6TgISpOO5IqWMowDZJPsKqW0qg84GfTpViGQ78gDPvSNIk/wBnydyvhsZw1TRvhCHYNjg57UwkSchRk+tS/Z3ICsU2kcdMVa8ir33JJQiqZAFKkEBepFV3JbbxtyO/NWzaxYy8rvjqPf8AwpHjQIf756L6CqbZN0UJ1UqAjAdKqyLnPmHp271fuIVRVYjb3AJ9qoSR7yN3y5PaoYrlaR+eBtx0yaiaTcvy8sffpU8sJ+bPOKaUVTnALDtQkxXKq8KVkbJPUiqlzOIzwh9Qwq1PIq5Pyjr2rFvJtqlsjJ96dgv1K+oXe4MoPsAO1ctqc7eUwLjcQR71e1K+SPcW+/jPtXJahqAkY7TyaqMQZNdzgKFYjao4FY89yCf7x9qURS3DZZsL61IVt7XpiR62WhDK4SeYZPyp6moxBltqfM3rVxI7m8IBysfoK27XT0tYwG5NO5Jl2OnhTukxmrbzxjMaDn2qeZGkYJEvJ4rc0Pw4XXey7nNUtTCpKxxmpW8ph3PkAms+OwJCsRnJrv8AxTphgjUEcVU0yxie36ZI5ro0ijhnJtnPXemoLJWUAMBXP6XeR2OvWlxcRiWKCdHeM9GAYEiu31yIpCQvSvObtdty+fWin7yaZLPp/wCMHxT8D+LPh0lrbRvJqQdGhieHBhI+983TGMjivmJtrXZ8j5UJ4BqLqpyaIV3OAOua05bLciOht2ls8oIBwcUXGlyD5iuR7VtaFb8LkVvyxwiAhlFStxydjziO32ylcGpJ7ZkHQ11VrZxzXwULxmtrU/Dyy2u6NOQKbj2LjPTU8x+ZT82TitGy1TysKxO30FW7/T2gyHQisC5Qxv8AL0qGk9zVNrVHW2mvQJ1BxTZtdjlk2wI276Vy0YjIzkg1r2M8NuV2IGc9yKhwSNFUcjpbGyN8hlnbHotUpVlspyud0WeDU1jPKWBZgqHsDWzNFDNAFIGMVzt62Z0RVtjNhn3jIFFTQ2+xsKpK+tFAFjBojXLjNSOMDiq7M2cisizag8uNM5FN/tOCBv3p2j1PSsOWSd1wmaz7+O4WMmTle4oSuGx09/rdmsWQ6njqDXI6j4jkZyEy69m7isK4dSSAWWqbttH366YUFuzCdaysi7cazeNw0rhfrVNrgyfM+WPvUDHcRkk1atbUytnoPSt1FLZHO5ye7IY1Zycj8KdNHIq+grobDTd5UIuasanojrGGxgmqWpDdjkoLZpDkmtWx09HJLDjFadlozY3HpVqW0aGIhOKJXM+Y4zUYxHcMq9BXa/BPxFpHhnx7puo69brLZRsQzFN3lkggPj2PNcfqkbJOS3eqajirWwpK6se5/tI+PvDfjO409PD6+dJASXuDHtyP7vPJrx+G3DIOOfaszlmAHWuo0OzaQIDUuPKgjoZotDztzmn20MjPtCkmu8bRYobRpGGWIrO8O6eZtSYYyKS1KjNpnPJb84kGD71ONNcjcmRXpF14WWWDdswR3rl7qxnspCjg7R0NYTVjsp1L6HMv5tucOMinx3GQME/nWyYFl+8MjvVa40onJhrK6Z1rQrR3BQ5ya1rLUZYxkNwB0rAkjlgYiRTUsU3TNS4lpnoeka6QgWXI/GuitdQEgBVgfxryuCdhgq3UYNbWk6m8UiR5wOhJrJxKTXU9TtZw4AXA9c1owybgSHyenBPFcRYahvIGSDiuo0+5XC5Iz6nisi7HQW5DDqMY71fVQSApB6YAPWqFsN3IC8+9aMC4A3IBzxn/ABq0Q2TeVKUUJGR/slsYpksboWGVDdyGzzVtIVkIwSAec5z+FLPCg6qoI6c5q7GfMZs8IIQ7i54J44qBoV3MGTJq66heR196hdCcAYA7k1JRmTIFXAByPXvWJeyuoJwFNdJPGz8BhgGsm8sEkYiQ5zSfkNabnF6jqgiY7lY/7tczqmrMSxhSTaema9Eu9JgUnCA1yPiOzEcMmxVAwcetOMQ512OCurqSUncxwe2apkgHOMmtIabK7bmHBq/YaDLNkleK1T6Dt1Od2zzHbGDj2rodL8PEwiSZeevNdHpHhpnlGF4HJNWdZkW1Uwx9RxxQ5WJs27Iwz5FpHgAZqvFHPdSfKp2npU+naVc6pe7VQnviuv07T1tl8tlwy8EVUFfVk1v3astzN0jRsMuVyx68V3mlacIYRtHNR6TDEh3PjNdBBJCvORW6SZ50pM4Hxrp7SW7nbyOa4jSpRHIVNeza1bxXdu4GDkV5Fq9m+mX7OFyhNa2urGU11GatELhCqjBNcDrGlssjcc16LZ3EUqsX4Paua1otLOwUZGaUU09CDh/sUucAZrT0zTW3hnFdJaWK7Azr+dXobJQwKjircugtg0pUQKpGCKs6nIiR7RjnvSzrGidQGqpBbSXtwq4JWlGyFZyZf8LWLTSmQrxn0ruVt0EOMAjFQ6NZJaWaqqjdVoRuVIJpOaR0RoSaOa8RaVDcWzbUG/2Fea6loFwjsQhK/SvZJljYNggkdRWBqUsfKMu3PeocuY3hS5Dx+e2aEkEGmxz7WAfOK63WLISktGo+tc5LZ4fDDFCl3CcNbxNnTBDMg/fEfU1qxMLdgu8N+Nc1a20sLbk+ZPStmCQKF8yI5PespRLi31Rtx3JlTCrmiixYFBtwtFY3NLFqSIgdKrSMsfUZFbMqDFYmpRdSjbTWSZTI3voY1PGPrWBq2qeZlUbI9qW7W4YlQQay7mzlQhmbr2FdEIJu7MpTaWhSmulIKlRmqeHlbgcVbe1JbJq/YWQLDIrp5ktjBQcnqZ8FnIzcKTXUaFpEk7qCpArb0PT4yRujH5V1UFpFEBtUDHpUqfVmsqSeiItL0WKBBxzio/EFhm1JUdBW5bggcHirEqLNEVZQavnRzuhJHltrcNGzI3UHFW50LICR1q5r+jvDO0sKkjOeBVCB2x+9zx2NDaaMHTcWc5q9j5shwOaxH05w2MHFd8kUczsTiqtxapuOMYoU7aAcvZaV84Y5NdnpNgEhU45FS22i3UNot3Jbutu33XK8GrdvKFiAVWz7Ck5NhYZqF20dv5Z+lbnw/wBMEs5mK8GsIWU97cqBEwTPUivSvDEcWn26qQAcVSkkio05PodE2mq0PAxxXG+ItHU7gUya7BtVAQ4IxWfLfQXGQ23PvUOUWaKnJa2PJr3SJYXLxA49Kox3HltskXB9xXq8enpczMwC+WnzEHv7VzniyGLUWVLS1SMpwSq4rKpFWudlCTb5bGF/ZMOp2uUHz4rmdQ0Oa1kbCk4rs9MSfTZ0eRCIwfwrr/sVrfKk2FKt1FYRlfRnRK8H5HiMcbqcMCKtKpXYw78V6B4k8OQrKXt0GPYVyy6ftl2sOh6USumOMlJXLulSuyrtOCOh9a7LRrlypVwCc965/SbZNwDrxXV2OnZ2lG2n36GsZItSOj05yQF5xW3H935wSvYGsfTkdU5Uj37Vs2wYj74x71KJZbg34BjBA9hmppiqqrfxN1IGKZBHIHyrL+FTeXI6kPOnB6YrZXsQ9ykRvcgjnpioXXGemTxVx49rHdLk9iKruiZPP40rMtWKrDAJxVK4RcZPBrRl5OADx3rOnA35aploMyrrgH6c1xGvEzXAiQHBPNdpqcgVGA4HrXGp++v2znaDVR3Jt1IbKxRpVQLXaw6bbJpqrGv7w9axbOJI7kbRya6W3wsW70qnLlJkr2K9vabru2061KrPcMFye1a/in4c2umC1nlPzudrtngmuOvTePq8VzauySRMGRl7EVvazrWta5aww6hP8kfICjGTTpyjZ8y9AlGaknF6dTFvLeLRr5ltnUkDqKpTXbyS+bjLnqKvxWBdzvJZverkWlLGhdwOelUrvY1k4talKCeR8HGKui72fKTlqVoY44zxzUZhT7OXUfPVJMycY9hX1AgFSvNUb3Tlvoi0sZ2nvU6EebymSatSzq1u0C/KzHAPpVK/cmUF2OXHhSJvmRnXPvVZPBubpZAzsobkV1N/dNYWSKwDPkYPrSaLf+VcebIG8t84A7ZrRSa0MJUU9bFHXvCsN0iT2hEIVAHVR1PrWFb+HWJIMz7RxXSXGpPDeyDJWNsnBrKs9U826uo4TiIDCg9z7UOTYlh0uhS/4R62R9zl3x71ZgFrbSBUjCt0q5byGe5WBc/KvzVh38Mq3Z3E8OMCpbdjaNJJmzbaohlkiPDL096fJqJEZaPr0rG+yFXMvO8GpoARvyMqTmpSNkkVJbxzdFj8pIOR61UvW849ckD86vXSI8nSqc8GSCvBovYGkZMkXYZwap3GlGQdDmums7HzJOR1q/dWscMQ3AA1F2yGuiPPYoXtpSjjitK2Cv8AIwz6VsXdnFcpwBuFV7WwaOQEjIqZSBLuENrs5SitmKEAcCiouVYfOny1j3NsZGJrdk+YYqtJFgHArNMLXOXntQhJNZV1bs7Ek4ArqL2EmqDWTSNgDrWsaliXTTOZW2LOeK0rW2MZGBWwNM8tM45zUqW3y9OatzJUUmWdMcoBitOO4bcoJz3NZdtHsPWrlspacmmnc0SRsTXWyJADgnvUovDGAOpPSqMcYlfLkkLTZQxnOzotUNJMvm7ikkMbjJ71TuYLWVCwjUD1xVQBljldfvMSKlvInXS8K2CeKFexLgmR22mwMA+0BT096tx6TaswLRgk8/hWfpbSs6s2SkYxirc0lyLmLaMK4xj2qo3MpUl2O2giF1pCwna0EfAHXAFZUFlbSylIETg4p2iLeQWsm3BjkPQ1V+xvBqaOspUk5KiqdyY0kjSmtDbEARAg+lNurZ0h8xHXj+DvV+C7Vd4mXPGBVObbtaUk7s4AqZRRrGLRUCytGCAQfSofLc85INa0WRhm5BH5VbgtYGw3qKnlTNL2MQzSJaPEVJJOQ47VSjEy/dXPvXYC1hERDKGqitsqudq8VMvMUGlsjmr+WSSzMTR8+uKl8MXEiZhkzjtmumNvE4Cug/KoH0yON98Qx3rCbuiuZbMS7hLpgrkY61x2pWvl3G5RyGr0KIAw4bnFcvq+xbs8DB4oUrrUlFfTIR5wyODXU2kHlgBxkE5BrH01FZsHqOldRZqCAW6dKUtR7F+wjKjK8qe1aKKi/wAJGfaqkELIcxH8KvK7FRuFSvMCWFwmRgHIx9KtRQwtD0Yt3J7VTiVCeTj1NW9sO35XbgetaQIkQTsCdqqOmOKqMM8t1HappZI8/Kp9PWq7c/dUj60NlpaDJW4xj86y75gF9/StN0J9AKpXMaDkDdj1pO7Gmjl9SDyEqnT1rGFqIJQGPOc11V18+QBgDvXN32VlJ54pwG9Qtm/05c4x0rpHZRGFB61zFiBMWJ4IOa1FmMhQdSvHFTJaks27WyXAYYJ7014CZj6U+KYpGoH3iKSSVywHINaKJmr3IjaKknB61I0G6MqW57UkkhIGTzULyvkFRmtL2HZsgmQKFJOR0pjQqXQK2FZaJCGDKcg1DEWUsME8cUc1i1HQnFu8eNnzuvIqm4JkkYpjP6GrlncGOQM56etOlkWV2yvDGq500KzTMrUUe6t4U2ggHrWlbWuIUVQNw56UghVXBibGOcGr0c8iLuVQOKIy1uKW2hha3ATMjGMEt8vtWXp+nJa3ahkBGNw+tdPNIryJvGQDVeYxCRmA+lDld3ErpWM5VA1CWVQEOAMCqF5CHut2MnNasm1y56E1UKNu9QO9DlcdirNHtQknmmxRrsqaeNnUioVRlHLVLkOxTuYwScCo44NxyauuqZ5NMLop4qOa4EtqqQjJrK17UELY9KtSzEhgtY82nSXMnPShyshxir3YumS+cG461t21uGHIqPT9N8mLAFasMO0DNQNoqNb7egoq83pRQKxkIM09otwpIhxVqJR0NZgUDYhslhTUtAG+7WyUyvFNCAdqAMiaDAPFVZIQBwK3JkzniqzRKT0p3FYxgnzVes4vmJpZbcKSRREzIfaqUrDLcUXz5HAzVhbZS7ECq0MpzVqGU5NaKQrMjFoGdVIwCat39kPs6JgEZyaYrhWFTNLwMnIzVKQndlC1tVhBGzrU8li3nxHFW0lUn5gKkadS6AHGKpSVhu5atbJkH3iPoaW4tQ0wIY7x+ZpyXQUD5qPtiLIWH3scVTmiUpEi2pgkQzqGBHAqYmCNyZFU+ntVF7wv1JPpUDSFh3JNQ6iWxSg3uWpZVyRHjGaW0l8w7WOKpRp5kgHIz1qZkeNyFXPpipcm9S+VLQ1I5hEGXqD3pyXUQHzAZFZiJNu5BwanW3BPXBppslxRoLdxPJlgADxSXTIiZDg57VWVVxhxyKryws5bBIA6ZqXG6I0TJYrncxTPFYmrAPdBVGadcSSQtlQaS1XzZtzDHH51itHY0t1EsJDFdeWxwSOK66wf5RxzXNTqhuY+O2CRW9YWxCAxsfoaTT6D3Wpuxy4wD8tSPdCFcnn8aowzMCqyLxnk1bkWF1zxmkr9Ckl1LGnXMt7uKRAKDjO4fyrTjJVcPGAcHHGT+tYkMKK2VIBrUijZ4z8+7B6e1b002tSKqV9NiGSRNxIGDUUkigdRmo54tjH5hg88VQlnUS7Sal6blKF9iyZWY8EBTUcowfmIIqFZCx+UE1IwwCZD07VKdyZRsZ10N5O0YFc7rW1IWJ4xXS3UqtGShGBxXI6w5lkCZ4J/OqRUEV9NYEkjjNW4JTDeD0PaqcWLc5Aqc9A+cE0Pe4SR00Ow4Zmq0HWRSBz2rAsroFdrda1ra6SNcBck1pzGXKP8ohzkZApGDNG20YX1pBO8rHoKSV1ROST7Cp5ikhmQVHy5I7io2JJIVcA1KtwqYIQkVHPco7HClc0rlWK8iqoywyc05H8xQuMU5sMmAuWPrUW1lVgDhqLMdx2Cr5xmnXF3+72gYqqZpB7kdqry3DMhDLg0bbCtcmadC2SaglnH4VBt3cnj2pkpwNm3ik2yrIcZRj680wSA5wcU1UXby1R7UBxmkrhZEjthclqoyszH5TVvC/WgKMYC0xWKHlSt0zUsdgzYLnAq4NwPCVMiSv8Aw4o0CzIoLJBjjJqwLVF5AAqRUlRR8tDs6j5hRcfKxyKoGMCo5CBwKQyZHSmMQV96L3Fy2I8gdaKgZsHrRSArRdKtQLk1SiNW4HqCEXo19al2D0qCJ881Yjcc5ouOwjW4YVA1ieoq6G44p2WI6UXRVmY0tocnI4qrJanPHFbkobPAquY5CenFGgWZli3dR0pyq4PStcRZHIpHiUc0xGUd+aP3p47VqJHH3xUoSPHGKaFczESTGad5Tk55rSGxT2pwePnpmmVr2KsVu5UZJxUyWo/jJzVhZOygYpGkCSdRzVWQtRkMZjyMZFTJDvYBc1Zt8AAyY9RSi4VZBwAM09Baix2ZjXd3NXbWErlmAYVHNco6DYDxU1tcxgD9Qad0iHzNCz4OCqgAdajNuJAH6DvVxpoSp+TBNVzPgeX2NF0JXIZYBkeWc1WnlCRFTwamnHk/MknXtms+4cv8zDIocrFWuZ9wQ7fMeKfC+1OgBHQ1Wu2AIJ6ZqW3JfG3NYt6mqjoWLaFpwZM/Mp4rc06Q7cHIYdazdL+8VPBrZ8ryyrx80PuD00L0WCc5FSGNZCB0NVYWVlLDIenxychZBhuxqbrqOKLYUggDJ96sIZ06MuOnNVA7oOzD35pY7mRZDtyD90kelbRHytj7gZk/ecZ9BiqbQxbugOBnpUt4H2qYSGPQg84qrb7n/wBYenX0pySGlpe5aQhYwc4A71S1C5GzGee2KS8ucqyr6YGDVaBQkfmTA78cA9qzb6IOXqyKWNnizI20enrWHLF9pvOOI04FbF9IX4j5LdhTBaLHGMde5FOO+gLTVmFfxGPd3APWnW5EgBbGMVNqwHlhVOTUEQ24BHOKbG1dEgQCQutaFi+5xu6etUFYcjPFTjIUbelCZDibRVC4CH8qjmCpnOTVO3d1wVNWxIzD5h9aq6JSaIzIWGI4yaYS0fJiJNaMLIq5UAE1ZgMX/LQA0reYXt0MRrqRcHysGh5pCuWTBNbkscLg/KM9qgaJG+UkAU9uoKz6GRzkMYyahkZf+eJzW8kQ24PIqKSBS3QflSuFkc8suHz5JxSu+9j+5IrcNuo5xTDGu7IHH0pXKsjDKDH+r5pfKQjlOTW79nU9hTXtx2A/Ki49DGitl67anW3HYVfES5waPLweKVwaKaxKPvAU7Kj7tWXVdvPWqj7QeKTdhJXHGTNMlwRyKikyDxTZHJWhN9SuUZKFwapu/UCpnbg81TlbrimKxDK2KKhkYluaKLEkaN2qzG2BVJWwatxEYGagzRajc1biz3qpDgmrsXHapNEWI2x2qTecfdpFYYp6kUykiKTcRkCoD5pOAKvbs09AM0DM8rIBUTLKxwK1JVB6U1Y+M4obAzkglJ5qQ28uMDrV7aRzUyDcORQmgaMs2UvcilWzI6tzWwig8EU8xL6VV0LUyEtioOWOe1C2u+QZz161reVk07Yir70XAptDtAQZyKVLTJyxq1vXgnrT1YGjmFysbDFtGMA08hUcZXmmNKV4AqGV2xlqfNZC5GyyZRnJ4qCacFvlqEEydelBQYwOtLmuChYR8ycE4NVpclME0+UlQQT+VVi+eO1FylAo3iYJIHArU0yIfZ0bPHUiq1xEzgY4q7pYyqof4eKNimtCxNA0TCVOncVp2eZo+CMDrSrGrxkMCceoqOw/dBx23cfSpe5G6NAW527lHI/Who1nQZGGHtyKVLgYIFRySYIYHrwfSm4rcaixY5wh2OevpUsijzVMZAbPOe5z29ahkRHTqcgZp8bebHgkgg9D6Va00G31RBdSs0xQAHPPy9xTbvclt8j7Nx6D29aszRFWEiITIoIK/wCz7/nVBlMkLOWynPT+VVbowT2KtmrTzMzg7c/TNW71x5WByx4ApIWZYMY2g85xWPJcSRzB933mwAaz2Rpyubv2NSygVR8/Mh6k1FONsrDeNvpUlpJ5qM5PHbFVbk4LFeQT61XTQzs7u5nTxeZdqFP14p0sKDlh07itCwjGWkfPzdKWWFRnuCM0+gnLWxgFP3rbPu5qyo2gZ6UgjxLI3vVlQrD6VKKbGROVbjpVpJC7VBgDOeKEYI1MFqaMeTwasIMEZqrA4PvVuFg3TqKaBjmcFvlFDAEjPGafsw3Sk2B2x0NAIWJHXAyCDSSKyy/Wp0iK4JPHakmUnmmlYm+pDtHJJqPIAOBTi4BwahJAYnPFJjUScOoTkc1Ex74pitlvallcBeKQ7DHIyeOlMJ3L6U3ORkjimeaoBANK9wsRyE5qvP64p8rbuRUDvheakqxE8hHQVWeTk9qkaTOc1HKFYUwIicg88VSdvn9qllfBIHSqzjjINUQxkrYoqKQkcUUzNkS5zVqJsVUQ8VNEfWoZKRowSYYVfWQYFZEbjNWVl49qk0SNRXyKlRqzoZTmrG85oNEi6pAPJqRQT0qtG2RVmN8DmgGTbO5oBAoDZPNTKgIoDYYvPangdaGXbTgvGTQARHGakzuPFQc59qmiBGaY7C7tmSxFRqyyMeaWWPcuOtSxW4RMnrSDQb5a9TRtB4AqVwOKchUds0CZAyVEyevSrzMpGMdarSgqpxzTYkQZC8jFQyHLcfpThluDTJTtIUdaSdxpFaTJbHbvSRx9yPxp8mGUnuKW2Usp3de1BXQkVAw5XJqa3hMUyhuEb19akt1yM7ckdatyR7ofcDg07XM27FyMDaMYxUVwqxOjLjBODSW0uY/Q4pJWaRcHHFPdERTuI7Im4rycZ+lWIWEkAXYjE8HB5qvG+9FXGOwx3qcOmyL5Pk68HqaEbvYjtodrMJc5BxkHtjNOVTFN2bv1606R2incgArgDmqu4tOzAhYxnIxyaLJaE6ss21wHimBY+YcjjPA9aqQ7RZPhgXZsEVJ5ezTndUwznPB/T+VZtjM0s8aEYQZI7k/XHWnzWtcaje9jWmVBb7FYbumB1rM1CGJYY8cMO4qxLOPMQBgVBwD0OKZe7ZHMYztHI96HqmOKaCziZUQYKqBTb6PLKFP3iBVveBCeMHgcVVZi92igHKnniqaSVjJt3uXVhVYQBwRVO4BQnB4PGKtmTKsCORzUFwAY1A/Wh6mUXbcoSRKynHBNRlCgB7GpFICsepB6UxDvVh6GpNEJKo8vdVfvnNPnYocEdRUI5Jx07mhs0ii1ay4rQgfBzmshVKkY6VeR/lHrQU0aayZ28VOqliCtZkUpwAa0YpSIzVLUhqwk8jY2noKjhmODk8UycnOc1GDzik7lJaE7spVs9arHH1qWcARqyH61AOmTRcaJF27cCoiM80m4KetAkGMGmFhJWwnHpVF+BnPNTyc9zVC4JDYGeKiQ0hzuFFVpHL5pzrkZNRldooSAhZwF561AXLd+aW6QkcVXQlTzTsJrQjl3b8U0/KtTSkZzVVm3E5ppGbIHkycUUEAnFFUQ0RrwtORjmiMcVIFAIrMmJIgPBqwrHb1qBRxT1HzDnikaouwkgDNWUbNVVcBR61PGwxmkWi1GSMdqtwsO9UkG41ehTApA2WlXkYqZCe1QJlsY6irSqduaYmI7ZHNIrcYxTuqdOaWMAHnFAIVRzyKlwM1DvxJTw4zQUSqnPAqYg7eKiRiT7VLnA6U7kMgfK8+lIrMFzjn0qSRec1GoYtyOKNiugSu2B60zf8vzCpnXgZqKRvlK44pMEV5MADbVN87s1YcYywPFVZWwMHlfSpsA0spPOOtWY+DxWYyvC248g81egk3EMeB0NUgZbtJCGKk8mr8suFHPAFZ7gJID1BGeKUu0pOCcHg01ojNq+pM0oR9o/wD11NC5kyHBAqjnc20dcA/rWhEp8l33AFPwzkgf1poroOtosKCw3AcAE/jT4dwny+FjVSQSM5Jqe3AXErAMoJAz/hTI3aSLMZw2T09M02rDuxsm9zGuBvz0/Oi35d3KkiVyF4xmp7aMKrLkB9pO48jpmoYcBod5Y46jpn6GjXRsE+glzEZLgxo2I1BA75FZ/kLDL5m5lAGOnvWpdZWJyqhAOQcckjsKaPntRvKCQrnpz24puN9youyMy5iMUblAGDYcM3WnBjPLG5Hz45A6VOhFxb4PHlnBI6/hUEaGJkWUEZOQexFCVimOddzHJIIwcUIQl0WGMbf1pZgxkZjuJOcnNRv8sqg5HGc+2OtMwlqiaY5GQ2RUFzKFOF6AU5GV1kGB8vFVbw4mj2nhsUvMz8gdQE9zzVd3CrgfeJ5p0rMWBP0qqZfmOOAaCojpX3Hcc0JggAHjNV88Eg9T+lWYiDgnBx0pGqJcKeDwBT1A3cHilSIMdw6VJt+bAFIpMljCnb61b3leRx7VSQYPXmps5ON2aExNEoIkyM4NMGB8rCmqRuA5zSSZEmQCMU9xk+75Np5FQkAHg02STK+hqOVvlHPNUgSH/KWyOtQSyLu4601jjpxUZHzZIpFWHmUgdKrTsCCQOatgAr81RTIpWr5Sbq5SZv3YNVWlIOKuShQpFVG4GcVLQyBySarSq3ap2Yk8UknA96CXoVudvNQlADVo5x0qrz5h3UzNsbtGaKccA0UEFONsVIWJ6VAlTp0qCUTIemamUZNViasQjcKk1RZVRipYuoGajwcCpEA3CixaL8KgfWrik5AxVKIjGatRvyM0WAtRtt+tWoZCy4xVPzBnjrU8bYHFGwmWGHy471FntSZPrQoB5J5oGh4BA6ZqaOP5OetMVjxjpUwORjNK1wuOTK49Kl3KBnNQ7TnAodM4yarYHqTqobkHNNLBScimAY6HpTJH5A6ikKw7zATyOKjcoN27vTmG7oM4qGVgFy3UdqTGVJzG3y5qpMu1sZJ+vepsOxYiPjNMlkZeGA2n17UrDehVk3beWHWmQz4BznAqSVwQRwc96ozKwbMfzYqrEX7m3BLuQY5B9anR8YyMD+tZmnS7kAPfgipl4nx1UH1oF1LcrhJj1AJ6j1rUwvlJGcZBDZ/Dism4j3hGHTk8eo6VfSQnYQBu28n0AB/oapaD6I0CwKxx5B+Qtz+A/pUcTslwscIwFXD4/iyc/wAqbAQbpVzjYo3HOBxzU9sv/LQA5fOM/oadrgtEPnTbbFkYq/XH55qG2wCgZQTt5PfFTtcKYxGU4OFHfmlCqzMsfO0YznoO+PenbXQadlqJPMDsCEFd+7b6emajlyrxyblO0EEenNWFjj2mJmUhQfmB61EsG+zkEJ3Nu+YKO2KvUaaRVDqss0Yj+bqPY1Wnz5kRcBRuwM+hq4D9nuP3kZMmMbc9h649qp3Bdg8cigAZcZ7cdKlFXuOJ/duqgDbg5qooeR1IJJ2bc/QULJmYbjuBTGSOmeRTdzJGh34UnPQ8kdaRDViSFSsj4GMjdVK5mUSjYcnJI4+tTPMwkfcSRjAyapbTG0gbJK54z1FLyMX3YXDlEyc4I4/SseSfazjIz6Z6CrF7LuiDAnOTgH8KyGhJ3OW5boKqw07I07dlcgr8x+vWr8fzKp4Gewrn0nMR+Y81oWl0du7g4qbGkTft2YFVyMHuanfjdt61jR3O/PPNX4ZFCgE8+tItrqXIo2Iy9Pk4YFRioFd+OeKmc5Qc5oQDYi3mc1LMeM4yKgLAqDk1LGQy4PNND8ysSWB4pCflAbnFSyjAJFVpJAHwDxVXKWoofccMOKa/TC1HK4UZzSxtuHUUhkgLEGoWfIwaR3KnHWmynEZwOabZLQyRBtJzVGdgy4HUVNI7FcY5qsAVB3dTRe4WGL0qGQsX9hVl8EcVA+QaCWRGQ4qEnLZNJITvwajLHJNDM2hXGRxRR1FFBmUFqdDxVdT2qYEVFhInTHrU8JIbjpVRW5q1bAZ5pWNUXhyoqSP3FMUjGBTuR1pjRYj65HIq2h4HY1TgbHFWCxxxSKLQcZ5qWJjnHaq0I3jmrAJ6CgZbHQU4KqnJNVVc9CcUrSAcE0mJIs+apOAelWIWUDJ61ShCdcjmrKuuOaBsnEmcnGKieUnhKDIoX1qu0h3cA4oEkWkztPPNMOd/JpvmbhxxTHlC9OtOwycs4PHAqFgS+GFQvcnscVXmuCRQKzJ5ndRwRisq9lbJGeKSa82khiTWXd3BkGV7U9xWJN7bvvE1ZiDOhYr14zWdamSVscVsW8TKmGJIB/CqsQ3qNgDRSAEHaeprRt2BdzHkkkDGPpVW6ZlAU8AHIxRAxUu4PHWpeglqaTOWwCcIF6Z696sWvmGUbRneD+XQ1RhZpNx42gD+VTwy/O7K5UhMg/n/AFpJ6lpaGpaqm4eYuerN3J/zitOEoyRCTCkDHzd/WsaB9rRqc79vJxVuzG4tLNIVUIxUHpz2xVp9Akr6lkstxcsY/lBJIOQMYH+Pak09BFGZCR3Jyccf5xVe1iBtSeidBn1NSSW7C3gAPbcTnqKa7h/duOhjbZMxU+owOMetVxKbWA7HLeY+eP0/mannkZJ0QvuVlJI9Mj+lR7FU7UIZo1wvP45/Wn6FJ9yK8umjRyUAATgg5I4/xqk8wuYE3JtJUDJH3j61Ne5WNd4BJbGPXiqFyZg5XZuUJwpGMGlfuXGK6Er5J4xt4yfX8aqsWHnIx+VeRk9BT1O+FGUZ5wRnp+FRzQ5mQ98478ihkyRHbzb1lVjvZRlSePakmBaMiTk9D6kUxFEIw5YkcDjoPc1Xac72JI+UY2+oFJeZjJa6Fa4ybdRgAr7VAY3kjGPlI6VZcA5/2uaiBOwnBHPPrVJktaGfdRbn+c/NjtVeOVo3wAcVdmj3ZJzVR42wASPrVONwjKxoWsycnaMnvWtBLEUGeSK5MO0Tdc1etrsnAzzWVrG17nULIrdGx7VKJWPA6etYcd2xA4FWY5nB65B9KCkjSZiyYWnwyYIBOMVUSTaAD1p5YNyDSsMfdSNk88VXZsr0xUpGVyahPJ9Ka0LiyJhuXg02NtvU1I3sKYqjJyKZVydDu5NMkIBOKazkEAVBM5OQKe5nYkdgF6CqU7g80u8kYJqCVipxjOaGK1gWTL4HSpJHSMfUVW4Bz0pspDLkGgmWpFJtZiSahPQ4NNcjPB5qJ29DxQQyTcegNFNUgCigyKkfIp4NRRnAp4GT1qQiTIeavW+SKpIB3qzCD68UGiL0JIOc1K7cVCm3GKl6CkykSRH0q3F9arwgdc1OrDNIbZYT5SKtJgDOao7+etWVYFPei4EhO5uaJiqKM801TgUOSV7UtykJDL8wFXlbHfNZYXnrVqMtgYOBTSKlYvMyiP3qrI5B4prtgcn8qrST7SabRMS0Jz1bioppQRhe9VvO3klRUTP82C22ixRI0hUHmq805x1omlUAjdk1RnkzwDTsQ2RXMpIOOtUg0jMRirOM0+GHc4wapIhysT6RE2/Mn3fUVvJGzOgPAJ65qjDGIiE646/WrqSBEIHOaJERTeol7+8XaDgjNV7RmUv3AHepyGLnPHpVY5j3HJzg1DKtoXreRd5UHk8fWniPETluGJ2/TmqFnJi4BHt+FXS4MOAc85FLcuOhdsHw+7O1gMZ/CtBZkSOR23FXXaOfU1n2qbUlyOdvUcgcHj+VW7RVkVUf7gxnHaqi2ipaliG2aaKOINtbfgHP5mpPNQvLGFOVBBOepHemwzn7WUVsxqOMjHPrU9u0LXJedQzSMWwMjH4VW2xDb6kdqZIvLaVQ3PVhkCqaKk80hjeTLZHAq+twTK0EQUx5/iHSq7J9lGIT9453DoaHsNPUJZYYZUhAVgUByf4TisyacRXf7sGRCNpBGQat3sSmXzHXy3YAg4x9MCqs+IZMvuC5GGznincuKRSuY2RsnbvBztHQ4P8AhTy64VVzljuwDUbSOsjbSSeoB7imOcCE9CD83akOWu4+dxLE7YAcn+lZEwHG0nr1rQumGEBGG5PHpWZKJFGCMDr9aT3MWi9HGDbK64JXBIP0/wD11XcfMGAPTkGpLNyMgjIIpc/MQelNkxKUzFfmKDAPeqksPzFmPynkYq9crnI61DaneWik54OO9VF30JlG2qKEtuCPlqqzmI8ittUAHPaqV3CDk4BFJjUrEUV0WAFXre4bIPWsgDDcVYjdlIGaVjVM3UuGbluKnEgK+9Y8c+eCasRz5BGelCRRo+eVOMUqyAms8Sl2x0qWKUIecGkWW2yc89aYzcDPWo5JTjg9elQM5PUnIoAeJPnPNNZyDniot4J96ZKfl4NMBWYHLCmFty5pitwaRjgfWgljZW6ZHFQF12kCnzN0AOaoux3HNMncSQ8nFRN25pGYg4ph470iJEhbjrRVaR+wooMmhENTo1VIzipQ/OKkmJajPzc1ZVz2qkPrUqSEcUGyNBHwRmrAkwPWs9ZOlTRMWakWkaELZBNWEY4qihIFTq2VxmgC4vzdalVwBjNUhKUxUyfPSGW0fPAHFPOcc1XRiBx2od2zkmgZKhwTTvMBGAeaqK6jPrSb8HdTGy7uyvWqc4APekE556CmySiqFexEJjGTUFxMWPFNmYknmq0j7Tk8miwN9Rzvn61GpyeaYHJap4gC2KDOUieJAME8g1chRVbzTwFqBdqDmp7j5YVQEfNzTXcz3GCYvNtXJJOSfStAbs9e2elUrQbBlmwByKvq2GBB6ioNvImRdwH940t3CoiJJ571LGnyZPUcCmTZMTFujc0yGZKgx3BGDn2rUWMh4CCCD1GOazxHtmDdVHU1pQsyyKyEcY71JSZfADRzBTgMNuKmRSFjRSckgk9qhiwlvKQQXIyfqaerTiOMDGwn0/z61ew0WGYLJtCkhupAxUuIhOZs7FUcITkmq97MoVUCEyEde1MRFCxuWO0dzRcpLQuJNCrEiIgycEZ5FSfKY1UZD9t3TFRQmN5cMGY9fwpyOTd+UcRLnC5OaZLIPtLyKUnAdYx8p7gDtVW4eKeBckk56elaN5byxIxAUnOGA71SithH82DhuuarXZjTW6M+REZRIFIGcHB5BrPPmPJK3mMUBJIPGas3MjF5o0DDngZ4NVhKQ6grgEYI/CpZepG0gwqk9c8mobrcdyjjHoelOnIUq3THvUQJc5/hB7dxTM2uosBBUKevpUrn5Bg9KizhgTn2z6VI7BowDgYJ96TRKIJT0J4GKpE7JCy/ezkHPSp53JHy8jNVZfu5yaFoDV0aIxJGrqRz1+tQzKMVDp77hJHkDjcM1O65HeiTtqZpGVNGQ5NRqzAnPNXp4mznHFU5DjihDTsSI+DViGTnI61QUknjmnxzFWIIp2NUzTz/ABdKaz45zUHm/L7UzJbocik0WmWfO3YqfcMdaobTuGasKdv9aENscxwc1EWJPtSu2DkdKiaTB4oFck39u1V55CBgUvmA5PeoXbIJpiFL4UHNQmQMckUKRnmq8rYJx0oJYTOO1QlvlzTZCetRvJuGPSmZyGu/NFQN1ooMyRWwadu+bNQ9DTycioIiy0shxU8RzzVGPI61ZifApM2ReVgRirMHA4NZqP8AMKvRHA9qRoXV96mRgBjFVAcjipkOFoGiwrE1IJNpqJGyMjikMgx70h3LUcpJ4qZmBXk1QDBRnNMaU7sdjVWAtttBGDUcjqO/4VWlmbHoKj3FuelFguTNIMnnrULyHBFRO4AzmqbzMM46UwuW3m4ODzVVnHUnmqzTkZwaiWTOSTTJbLqOWatWzTdyay7Bd7ZrahGzFDMtyYINy5HBPeobplM5weF6VbilUnBwTVBstLzzzwRR0GnqXIcMAegxjJqaM/MRkYziqcT9OaniwrBiOc9qlGyNmHbjB5PXmo7mQEMqngAc1WRi7kBuox9KbIWWMDcOB2pkNETg+YCec+1Wo5cTfN6BeKrjAcZweOwpYpN6kkYwePU0mNGyBu3AEDJHSrcbFW25KjPGTmsq0diBzmrqyNvbbjcBjkcUxpGhJENquzKFJwQe/emSsZ5OVVUQ4AUYFVZfMaBcuCI27e//AOqp4ZwByO2KL9BodtIJZckH0HSornLMNrlW46DofrU5ctFz90EcZqBgVL4bKkgn0pWGmBlnGx95Ixgk81WtnmPmfvC6kkjbz9fpT2RobzEm/awxtpILbyHkYMA3IxmrSuDtYq3hCuRtVunIFUJTtlKkAHrwORV2aQrvEuHOPyOaz7j5n3Z/h3YPtTGiKbBbaGGaiddvJOcgY/XrSs3yhjgYqMsXbavBAyfeghiuPl4Y8dM+lQwzqZCCBx2p6c9x6YqCWBUcnGD7UNCVtmKV2zZGNh5FVpW2OV6qelSyHIwPuiqo4zuJzSsJklpKEvULHAPFaikE4rAyRMmfUYrZQjcQuce9KWxEdyWVRtIrEvEKMSM4rZcjAyaoXigrxUp9AasZW8gfKcVEt1h8NRN8jmmAK7AtxirWhcZLqaCOSAe1To+OQKpB8fKOlS+YRgUx3LCTfNtqwj9881mEnceanWfAAoRRZmcbevIqpIxJG2llfIxjmkCEKCKTBMUFgMkU3cBwR1pHlO7nHFRyTAn2oE2MmfBOKqvITU0s8W3pzVKRiTxTJuPZzjmoHIA4pztxyahkYEcUzNsUniioi3FFBi2TScNSqeKST7xpmeazJiybecVJE/c1EuCKkjwKDdMuREdasByOlUUbFWUIIpGiZeilyKnDZUc1nxHmrKtSGXFbHepNykVR3kYqVG3DnFOwy2rIByc1FK654quW54oaQ+lNAK8mQQajEvBqFpACdxqHeM8U7ASSSVWll5pjs2TngVWlkA70xXEaQ5IxToFMkmKrbyzhcVsWEGME0ENmlYxbI8DrVvLL9KZAMCpiArcms9yoqwkcirIp/i9Krl8znPHPHai7ZQm70NU3kCyAk9egHSr6Evc0QyFsnOQD3qeIgMuSQT71Qtyfz4q44G1cZGO9JI2TNMMAh2bc9vQUyXIxTIWCx5J9xUjNnZkjpmgljSny7s/N70RAbjgDNKSu/sx9j1p/STgY55FAItWu4RhhgnO3pVuMDyvvfMxzWfak5AA+XPOK1o0XIQcgKDmnbQp6E6wFkDOR8o4561AxaQnGFGc4xVjcotwFHzjgYptspOVYhT2z3NJxEnbUfEyZ55bHQ1IYWMRxt+XpVmWFJkWQROs6dWUfKRUID+buWPc2MHPP41fKTzX2K4cyuvnH96oyOOuOgqtqJ88eap2EPhlHrVu8j2qJIn3Nu+cdwKo6kdgHlMzKfmYHp7U35jW6sZ7ymWR/kPAJPFUbn7gbHzH3qYTuWkCkBR1FVrjJZiPXIqLmqG7VdSrcmqwkMUylcqBwasoGVyfX8qhkIDHAyOuapbEXEZfmUDoOeaSeUeW3GeQc/gaSZ8xgg1SuJdgOTweScUzNiCYZxxt96ZNwp+lZ7ShWwD35weKluLkbQMjHrSJkxFO65jGRy3p0rbiOfm/KuZt5dzks5B6D0NdBay/IM9hRImHctHDL83Wq8w44qXzNw7VHJ0qLGpiaghDZFUlfI962bhNwNYV3GYnJ7Va1MtmTxuc8mpUlycE1nxyZ+lTA7jxTsaXNIOoPNKWHQdaoBmX608FqCky+hI+hpzNleDVdHKrg1E0mDStYVyeTAU561WfG3k0qtuzk8VXmHXJNCFcbIR0p0SqwOW6VUPLdaG+71p7ibJrkxlRtbJ71UJAOKcCF7VG5Bz60WMm7CMaKjY0UzJsvy9TULnFSydTULc1mTFj0ap4qqxnmpFbnFBtFlwYAqWJx3qqH4609G5FI0TLZmK1NDMrd6pk5+lMQkNgdKDRGqzgigS4GBUKMNnrTS2OgphcsrJ70yWXIwT0qDBIJFRsfWgVxZGLHrTNxU5prNgYqNzgcGqFcJpsk1RmbrzUspxk1XjXzZfanYTdi1p8W5wTXQWykdKpWkARFrTiGFyKiTFFX1LcJ496HYZHeo1f0py8kmoNStqgZYCKxrCdppSuctH3I7Vuz/v4yCa42+drK93KSozyBVJ6ktXVjrbeQFMZwT+lWdykg9QO9ZGmXMU0AcuAhHAPrV4PtXaBhj2qmrExl0NQEFe5NPiwQpzkVRSY7evI4xUisF25PTtSsXcugnJY9c1PBLufKjn3qnG5dD0PY1NEc9Mgk9fpSYIu2y+WxLZOSfwrTgfagOcZOOnasb5yDsznOOa0rTewOTyAKEy2aiIJJZCp9xnsKuabbhnYk7ourDHXFUoF2SFc9ccZ6Cr9u6oPkBKucfStYruYybtoad6QZFMIVUIA+XjNUVt9pJVmGCeD606W6VnEWVVQcA4qdEUuQzfKBkE9K1tcxTcUZNxOnnZhTKuNrD0NZF9GUmO1iWABYe1bEsiJvjToxOc1lSYVpGeV1YryT/Ks2dEdDJeJYpGfGQ3YVBesoIG0jIBqWe4GWKKVHbJzWc0wdiCM4rNeRpZ7sJJQUYZx71TaY7sA4HTPrSTviTrhT2qlPMNxAOB0571aFoXJZRs+8ODWdPNuBGf1qtNcFQQSOPSqD3LE7iDt96LGbdiyc5B3YHUH1/wA4qpe3ShSu7HGPpUEt2iKXY52HoeM1z15ftcTFYyQpPJ9aaXUyb5nY39OuGubxUDMY04ArsYceVgdcVyHhiAq27FdhFjHTmobuapW0QByoANKWJBzSsPakGNvXmpKuMbO3pxWXfxb1OK1iRtxVWRQSaadiJK5zSAxuQ1WV5GVp99BtfcBVdeOlWJMtKwPWnCTFV8kduKeOTxSGiyJMpzUe4k0i9OadwBnvQFwbcOT0qObG3rk0OxK1XfdnrSFcTgDnrTQcdaVgAM96bn5aYmyOU8cVFT5D2qEnApmTYM2KKhc0UzM2H5NQsKKKyBEecGnqcmiig0RIvFSq2BRRSNESqdwpy4WiigtMmjfFPLHFFFMA39qhkJJoooGRNypqEnqSaKKsllWdyzbRWhp9vgAnFFFMlmxCvFWkHFFFYmqJIxk4qdFzRRSQ5MVYOCR3rlfEloAS5AoopsUXqc7bXklrKMElAeVz1rqYJzJAs4ACnAwDg5xn8qKK0WqM6mjui1bzLtyFwO5yTnnrVxJiwCqMY9aKKC0y5HIBHjJJq5A2xFUjnqKKKTHE0MguoA6gVbiKwsSxIyKKKlblEglCSLIMggdu9TpcZjKhiD9KKKpMTQqyMoHPPrT5L6R1O4+nA9KKKq7JSTCO4hjDvtO5hgE1nXNxv3FumaKKGylHqZOpyL5Lbep4rn2mIU+3eiil1NorQpz3WVbrnNZdxcHJycEd6KK0M56FRpGPPOCQGGcVHc3MUce+NT5fJ2sc9+n/ANeiiqSOOcmc1qN2ZpSqZVFJH1p+mW/myqPeiipmyqZ6BpNuIowMAcVqw5DGiisjQeSWP4Uxl4z3oopFIj5GfWo3BOaKKQylcruGKzG+R8dqKK0Wxl1LCrkUYA6UUUDFpB1oooYMRiBGagJoooEQuc8UmflxRRSFIgkNQMaKKtGUtCInNFFFUZtn/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wrinkles on the dorsal and lateral nose can occur during contraction of the upper nasalis muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    \"Bunny lines\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 248px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wrinkles on the dorsal and lateral nose can occur during contraction of the upper nasalis muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7364=[""].join("\n");
var outline_f7_12_7364=null;
var title_f7_12_7365="Acetylcysteine: Patient drug information";
var content_f7_12_7365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetylcysteine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=see_link\">",
"     see \"Acetylcysteine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=see_link\">",
"     see \"Acetylcysteine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acetadote&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Acetylcysteine Injection;",
"     </li>",
"     <li>",
"      Acetylcysteine Solution;",
"     </li>",
"     <li>",
"      Mucomyst&reg;;",
"     </li>",
"     <li>",
"      Parvolex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691444",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop problems after an acetaminophen overdose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691466",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop kidney problems caused by dye studies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin mucous so it can be taken from the body by coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701434",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetylcysteine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only as a liquid (solution) by a special machine (nebulizer) into the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695461",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with juice or soda and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened vials in a refrigerator. Throw away any part not used after 4 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12415 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7365=[""].join("\n");
var outline_f7_12_7365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130167\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130168\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015786\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015785\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015790\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015791\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015793\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015788\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015789\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015794\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015795\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/1/20504?source=related_link\">",
"      Acetylcysteine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/41/16022?source=related_link\">",
"      Acetylcysteine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_12_7366="Placement of laparoscopic monitors at foot of table";
var content_f7_12_7366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Placement of laparoscopic monitors at foot of table",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 617px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration shows the monitors placed at the foot of the table in preparation for a laparoscopic pelvic dissestion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7366=[""].join("\n");
var outline_f7_12_7366=null;
var title_f7_12_7367="Classification of trauma in children";
var content_f7_12_7367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification of trauma in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7367/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7367/contributors\">",
"     Tom Brazelton, MD, MPH, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7367/contributors\">",
"     Dennis P Lund, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7367/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7367/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7367/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7367/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/12/7367/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury is the leading cause of death for children and adolescents in the United States (",
"    <a class=\"graphic graphic_table graphicRef67131 \" href=\"UTD.htm?26/29/27102\">",
"     table 1",
"    </a>",
"    ) and most high-income countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/1\">",
"     1",
"    </a>",
"    ]. For every injury death, an estimated 18 hospitalizations and 233 emergency department visits occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/2\">",
"     2",
"    </a>",
"    ]. Most of these injuries are caused by motor vehicle crashes, falls, and burns; many are preventable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=see_link\">",
"     \"Overview of pediatric injury prevention: Epidemiology; history; application\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12106?source=see_link\">",
"     \"Prevention of falls in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Types of prevention include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary injury prevention seeks to prevent the incident (eg, motor vehicle collision) altogether. An example of primary prevention would be road construction that separates the directions of traffic with impregnable barriers so that head on collisions cannot occur.",
"     </li>",
"     <li>",
"      Secondary injury prevention decreases the likelihood of serious injury during a traumatic event. Seat belts or air bags would be an example of secondary prevention.",
"     </li>",
"     <li>",
"      Tertiary prevention minimizes further deterioration and reduces complications when injury is not prevented by primary or secondary means.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tertiary prevention entails rapid identification of children with major trauma in the prehospital setting so that appropriate management, destination, and utilization of emergency department resources can be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States, experts have developed a field triage guideline that identifies those patients who warrant direct prehospital transportation to a trauma center. This critical field transport decision requires the evaluation of vital signs, level of consciousness, injury anatomy, injury mechanism, and special patient or local emergency medical systems considerations. These guidelines recommend that children \"should be triaged preferentially to pediatric-capable trauma centers\" (",
"    <a class=\"graphic graphic_algorithm graphicRef81002 \" href=\"UTD.htm?22/18/22822\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, seriously injured children require skillful assessment and treatment by clinicians experienced in pediatric trauma and rapid evacuation to a regional pediatric trauma center, when available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The introduction and spread of statewide trauma systems, the adoption of the American College of Surgeons' (ACS) Trauma Center verification for hospitals (",
"    <a class=\"graphic graphic_table graphicRef66042 \" href=\"UTD.htm?19/9/19612\">",
"     table 2",
"    </a>",
"    ), and the resulting development of trauma registries and databases have allowed for more accurate categorization of trauma patients and system evaluation. This work has directed increased attention to the resources required for managing trauma, especially pediatric trauma. The different types of pediatric trauma classification systems and their uses will be discussed here. Evaluation and management of pediatric trauma patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF TRAUMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of pediatric trauma classification systems are used to predict morbidity, mortality, and resource utilization (eg, diagnostic studies, specialized personnel, operative intervention) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One classification is based upon three categories: body region (local or multiple), mechanism (blunt or penetrating), and severity (mild, moderate, or severe) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other classification systems are based upon physiology, anatomy, or a combination of physiology and anatomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Objectives",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two primary objectives for trauma classification [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Triage decision support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triage decision support classification systems are often used in the prehospital setting to guide transport disposition. They are based upon rapidly obtainable clinical findings. They are designed to identify patients who have a high likelihood of critical injury that may require trauma center care for optimal outcomes.",
"   </p>",
"   <p>",
"    Since trauma is a time-sensitive disease, early, goal-directed therapy and prompt referral and transport of injured children to the most appropriate level of care are critical to their survival, overall functional outcomes, and the efficient functioning of the trauma system. In highly evolved trauma systems, triage and transport may begin with prehospital providers. Physicians and public alike should insist on a high level of pediatric education through accredited training programs and accepted national credentialing for prehospital providers, thereby creating an essential foundation that assures optimal age-appropriate, competent resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Severity of illness or mortality prediction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severity of illness (SOI) or mortality prediction classification systems are often used retrospectively to standardize outcomes for research purposes. They may also serve as a prognostic indicator in individual patients. However, they are not used to guide early resuscitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Physiologic systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triage scoring systems typically are used in the field to determine physiologic risk and referral pattern for prehospital providers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/9\">",
"     9",
"    </a>",
"    ]. They are designed to standardize the initial assessment of trauma patients, based upon the injury mechanism and physiologic or physical examination parameters.",
"   </p>",
"   <p>",
"    The ideal triage score should be simple and easy to calculate but sensitive enough to include all patients who require a higher level of trauma services. Examples of triage scoring systems that have been validated for pediatric trauma populations include the Pediatric Glasgow Coma Score (GCS), Trauma score (TS), Revised Trauma Score (RTS), and the Pediatric Trauma Score (PTS) (",
"    <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These systems work best for triage purposes when combined with information about mechanism of injury and anatomic site of injury.",
"   </p>",
"   <p>",
"    Each of the existing systems has strengths and weaknesses that derive from their components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Glasgow Coma Scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Glasgow Coma Scale (GCS) constitutes a widely applied scoring system for all trauma patients. Although commonly used for field triage decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/13\">",
"     13",
"    </a>",
"    ], the GCS is also an important component of many severity-of-illness scoring systems. Modification of the GCS to pediatric patients has been an important advance in the assessment of age-appropriate behavior in both verbal and preverbal children (",
"    <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"     table 4",
"    </a>",
"    ). In addition, the GCS has been shown to have prognostic value, especially the motor component of the score [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Trauma score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TS includes five physiologic or physical examination components, including the GCS (",
"    <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"     table 3",
"    </a>",
"    ), that are scored and added together to determine the TS value and probability of survival. The TS is limited by the use of two subjective measurements (respiratory effort and capillary refill) and may underestimate the severity in the hemodynamically stable patient with an isolated head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/6,18\">",
"     6,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Revised Trauma Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RTS was developed to address some of the limitations of the TS; the subjective components no longer are incorporated (",
"    <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/18\">",
"     18",
"    </a>",
"    ]. Pediatric trauma experts have expressed concern that the RTS is derived from adult data and that the components may not be directly applicable to children. However, comparison of the RTS with the PTS has not shown any major disadvantage to using the RTS in injured children [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pediatric Trauma Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PTS is patterned after the evaluation process of the Advanced Trauma Life Support Course and is specifically designed for triage of the child with traumatic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/9\">",
"     9",
"    </a>",
"    ]. It is the sum of six measures incorporating size as a surrogate for age and vital signs plus organ-specific injury data (",
"    <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"     table 3",
"    </a>",
"    ). The PTS correlates well with injury severity, mortality, resource utilization, and the need for transport to a pediatric trauma center. However, it can be a poor predictor of liver and spleen injuries for children with isolated blunt abdominal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Age-specific pediatric trauma score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age-specific pediatric trauma score (ASPTS) age adjusts blood pressure, pulse, and respiratory rate and combines these with the GCS to predict injury severity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/21\">",
"     21",
"    </a>",
"    ]. This score has lower sensitivity than the RTS but is more specific. The ASPTS has two major drawbacks. First, the user must know the range of normal vital signs for children of all ages. This significantly limits the usefulness of the ASPTS in the field setting. Second, the ASPTS has not been validated in pediatric trauma patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Anatomic systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;In comparison to triage scoring systems, injury scoring systems are based upon anatomic injury and are only accurate after all injuries have been diagnosed. Injury scores remain constant once all injuries have been identified. They are used primarily for comparisons of injury severity among trauma populations, but they may accurately predict risk for adverse outcome. Examples of injury scoring systems include the Abbreviated Injury Scale (AIS), the Injury Severity Score (ISS), and the Anatomic Profile (AP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Abbreviated Injury Scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AIS was designed to categorize the injuries of victims of motor vehicle collisions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/22\">",
"     22",
"    </a>",
"    ]. It scores injury severity from 1 (least severe) to 5 (survival uncertain) within six body regions:",
"    <span class=\"nowrap\">",
"     head/neck,",
"    </span>",
"    face, chest,",
"    <span class=\"nowrap\">",
"     abdominal/pelvic",
"    </span>",
"    contents, extremities, and",
"    <span class=\"nowrap\">",
"     skin/general.",
"    </span>",
"    Nonsurvivable conditions are assigned an AIS of 6. The AIS does not accurately measure the effects of multiple injuries. It is used in coding injuries for other scoring systems or for outcome analysis systems [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Injury Severity Score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ISS is calculated from the highest AIS for the three most severely injured regions as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;ISS = (AIS1) squared + (AIS2) squared + (AIS3) squared",
"   </p>",
"   <p>",
"    The usefulness of the ISS is limited by its inability to adjust for the cumulative effect of coexisting injuries in one region (eg, subdural hematoma and intraparenchymal hemorrhage), the lack of a direct linear relationship between increasing score and severity, and the lack of consideration of preexisting conditions that may affect outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The ISS should be thought of as an ordinal scale, not a quantitative scale; ie, a score of 50 is not twice as lethal as a score of 25. Nonetheless, the ISS is a valid predictor of mortality, length of stay in the hospital or intensive care unit, and cost of trauma care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anatomic profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AP uses the AIS descriptors of severity but uses only four body regions:",
"    <span class=\"nowrap\">",
"     head/brain/spinal",
"    </span>",
"    cord,",
"    <span class=\"nowrap\">",
"     thorax/neck,",
"    </span>",
"    all other serious injuries, and all non-serious injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H770250\">",
"    <span class=\"h2\">",
"     Mechanism of injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanism of injury is used for field classification of severity of injury and need for transportation to a designated trauma center (",
"    <a class=\"graphic graphic_algorithm graphicRef81002 \" href=\"UTD.htm?22/18/22822\">",
"     algorithm 1",
"    </a>",
"    ). In an observational study of 35,097 pediatric trauma patients (age two to 18 years), the mechanism of injury was also associated with mortality and functional outcomes with the greatest likelihood of mortality occurring in victims of penetrating trauma when compared with blunt mechanisms (eg, falls, motor vehicle collisions, bicycle crashes, pedestrians struck by a motor vehicle) and the greatest functional morbidity occurring in pedestrians struck by a motor vehicle [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Combination systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcome analysis systems use both physiologic and anatomic data to estimate morbidity and mortality for an individual patient or for trauma populations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/9\">",
"     9",
"    </a>",
"    ]. Examples of trauma outcome analysis systems include the Trauma Injury Severity Score, a severity characterization of trauma, and pediatric risk of mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Trauma injury severity score (TRISS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;TRISS analysis combines TS or RTS (physiologic) and ISS (anatomic) data and age to estimate the probability of patient survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30733506\">",
"    <span class=\"h3\">",
"     Pediatric age-adjusted trauma injury severity score (PAAT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PAAT combines the age-specific pediatric trauma score with the injury severity score [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/30\">",
"     30",
"    </a>",
"    ]. This score was shown to better predict survival than the trauma injury severity score (TRISS) and the &ldquo;a severity characterization of trauma score&rdquo; (ASCOT) in a retrospective analysis of 7138 pediatric patients from a regional trauma database.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     A severity characterization of trauma (ASCOT)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ASCOT combines RTS (physiologic) and Anatomic Profile (anatomic) data to calculate probability of survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Pediatric risk of mortality (PRISM III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PRISM III score is a scoring system used in Pediatric ICUs to control for severity of illness or injury when comparing patients within and between ICUs but is not designed to compare individual patients. It is the only validated predictor of critical care outcome in pediatrics and incorporates information regarding cardiovascular and neurologic parameters, as well as acid-base, electrolyte, and hematologic values [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/32\">",
"     32",
"    </a>",
"    ]. In a retrospective study of 125 pediatric trauma patients, PRISM was a better predictor of resource utilization than was ISS, but underestimated mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/33\">",
"     33",
"    </a>",
"    ]. PRISM III is proprietary and available only through membership.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pediatric Index of Mortality 2 (PIM2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PIM2 is available as an on-line mortality prediction calculator. Collecting only 10 variables, it is comparable to and faster to use than PRISM III (",
"    <a class=\"external\" href=\"file://pedsccm.org/Software.php\">",
"     file://pedsccm.org/Software.php",
"    </a>",
"    ). Validated only in Australia, this second generation tool uses data from the first hour of admission to the PICU and has been shown to have comparable performance to PRISM III in certain countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     International classification injury severity score (ICISS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICISS is based on the anatomic injury diagnosis from the international classification of disease, 9th revision (ICD-9). A survival risk ratio is calculated for a population based on the proportion of fatalities for each diagnosis. The probability of survival is then derived by the product of survival risk ratios from the three most severe injuries in an individual patient. The ICISS has shown good validity for prediction of mortality and resource use in adult [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/36\">",
"     36",
"    </a>",
"    ] and pediatric [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/37\">",
"     37",
"    </a>",
"    ] trauma patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30733484\">",
"    <span class=\"h3\">",
"     Pediatric trauma BIG score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The BIG score is calculated from the admission base deficit, international normalized ratio (INR), and Glasgow coma scale (GCS) as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    BIG score = (base deficit) + [2.5 x INR] + [15 &ndash; GCS]",
"   </p>",
"   <p>",
"    It was derived and validated in children and appears to predict mortality well regardless of whether the victims have blunt or penetrating mechanism of trauma. When retrospectively applied to a sample of 707 children, of whom most had penetrating or blast injury, the BIG score was more accurate in predicting mortality than the revised trauma score, injury severity score, age-specific pediatric trauma score, or pediatric age-adjusted TRISS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREDICTIVE VALUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abilities of 11 trauma severity scoring systems to predict survival, duration of intensive and overall care, and persistent disability were compared in a retrospective study of 261 children with multiple injuries; the mortality rate was 26 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7367/abstract/6\">",
"     6",
"    </a>",
"    ]. The major findings are summarized below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Physiologic scores were better able to predict survival than were anatomic scores (79 to 86 percent versus 73 to 79 percent); combined scores offered no additional benefit to predicting survival (75 to 80 percent).",
"     </li>",
"     <li>",
"      The combination of physiologic systems and the ISS (TRISS) increase the ability to predict morbidity.",
"     </li>",
"     <li>",
"      Trauma scores designed for pediatric use (eg, PTS) were no better than trauma scores in general (eg, TS, RTS).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction and spread of statewide trauma systems, the adoption of the American College of Surgeons' (ACS) Trauma Center verification for hospitals (",
"    <a class=\"graphic graphic_table graphicRef66042 \" href=\"UTD.htm?19/9/19612\">",
"     table 2",
"    </a>",
"    ) and resulting development of trauma registries and databases has allowed for more accurate categorization of pediatric trauma patients and system evaluation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Triage decision support classification systems are often used in the prehospital setting to guide transport disposition. By necessity, they are based upon rapidly obtainable clinical findings. They are designed to identify patients that have a high likelihood of critical injury that requires trauma center care for optimal outcomes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Triage decision support'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Physiologic systems'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Examples include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Glasgow coma scale (",
"      <a class=\"graphic graphic_table graphicRef59662 \" href=\"UTD.htm?2/58/2989\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Trauma score",
"     </li>",
"     <li>",
"      Revised trauma score (",
"      <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pediatric trauma score (",
"      <a class=\"graphic graphic_table graphicRef52562 \" href=\"UTD.htm?33/37/34397\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severity of illness (SOI) or mortality prediction classification systems are often used retrospectively to standardize outcomes for research purposes. They may also serve as a prognostic indicator in individual patients. However, they usually are not used to guide early resuscitation. These scores are based upon anatomic site of injury with or without other clinical data. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Severity of illness or mortality prediction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anatomic systems are calculated once all diagnoses are known. These scores remain constant over time. They are used primarily for comparisons of injury severity among trauma populations, but they may accurately predict risk for adverse outcome. Examples include the Abbreviated Injury Scale and the Injury Severity Score. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anatomic systems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination systems use both physiologic and anatomic data to estimate morbidity and mortality for an individual patient or for trauma populations. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Combination systems'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Examples include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      International classification injury severity score (ICISS)",
"     </li>",
"     <li>",
"      Trauma score and injury severity score (TRISS)",
"     </li>",
"     <li>",
"      A severity characterization of trauma (ASCOT)",
"     </li>",
"     <li>",
"      Pediatric risk of mortality (PRISM III)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/1\">",
"      Krug EG, Sharma GK, Lozano R. The global burden of injuries. Am J Public Health 2000; 90:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/2\">",
"      Burt, CW, Fingerhut, LA. Injury-related visits to hospital emergency departments: United States, 1992-95. National Center for Health Statistics, Centers for Disease Control and Prevention. Vital Health Statistics 1998; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/3\">",
"      Engum SA, Mitchell MK, Scherer LR, et al. Prehospital triage in the injured pediatric patient. J Pediatr Surg 2000; 35:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/4\">",
"      Sasser SM, Hunt RC, Sullivent EE, et al. Guidelines for field triage of injured patients. Recommendations of the National Expert Panel on Field Triage. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/5\">",
"      Tepas JJ 3rd, Ramenofsky ML, Barlow B, et al. National Pediatric Trauma Registry. J Pediatr Surg 1989; 24:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/6\">",
"      Champion HR, Copes WS, Sacco WJ, et al. The Major Trauma Outcome Study: establishing national norms for trauma care. J Trauma 1990; 30:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/7\">",
"      Marcin JP, Pollack MM. Triage scoring systems, severity of illness measures, and mortality prediction models in pediatric trauma. Crit Care Med 2002; 30:S457.",
"     </a>",
"    </li>",
"    <li>",
"     Ruddy RM, Fleisher GR. An approach to the injured child. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1339.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/9\">",
"      Furnival RA, Schunk JE. ABCs of scoring systems for pediatric trauma. Pediatr Emerg Care 1999; 15:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/10\">",
"      Eichelberger MR, Gotschall CS, Sacco WJ, et al. A comparison of the trauma score, the revised trauma score, and the pediatric trauma score. Ann Emerg Med 1989; 18:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/11\">",
"      Tepas JJ 3rd, Ramenofsky ML, Mollitt DL, et al. The Pediatric Trauma Score as a predictor of injury severity: an objective assessment. J Trauma 1988; 28:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/12\">",
"      Aprahamian C, Cattey RP, Walker AP, et al. Pediatric Trauma Score. Predictor of hospital resource use? Arch Surg 1990; 125:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/13\">",
"      Beskind DL, Keim SM, Spaite DW, et al. Risk adjustment measures and outcome measures for prehospital trauma research: recommendations from the emergency medical services outcomes project (EMSOP). Acad Emerg Med 2011; 18:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/14\">",
"      Bruce, DA, Raphaely, RC, Goldbert, AI, et al. Pathophysiology, treatment and outcome following severe head injury in children. Child's Brain 1979; 5:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/15\">",
"      Young B, Rapp RP, Norton JA, et al. Early prediction of outcome in head-injured patients. J Neurosurg 1981; 54:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/16\">",
"      Hannan EL, Farrell LS, Meaker PS, Cooper A. Predicting inpatient mortality for pediatric trauma patients with blunt injuries: a better alternative. J Pediatr Surg 2000; 35:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/17\">",
"      Ross SE, Leipold C, Terregino C, O'Malley KF. Efficacy of the motor component of the Glasgow Coma Scale in trauma triage. J Trauma 1998; 45:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/18\">",
"      Champion HR, Sacco WJ, Copes WS, et al. A revision of the Trauma Score. J Trauma 1989; 29:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/19\">",
"      Kaufmann CR, Maier RV, Rivara FP, Carrico CJ. Evaluation of the Pediatric Trauma Score. JAMA 1990; 263:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/20\">",
"      Saladino R, Lund D, Fleisher G. The spectrum of liver and spleen injuries in children: failure of the pediatric trauma score and clinical signs to predict isolated injuries. Ann Emerg Med 1991; 20:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/21\">",
"      Potoka DA, Schall LC, Ford HR. Development of a novel age-specific pediatric trauma score. J Pediatr Surg 2001; 36:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/22\">",
"      Rating the severity of tissue damage. I. The abbreviated scale. JAMA 1971; 215:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/23\">",
"      Baker SP, O'Neill B. The injury severity score: an update. J Trauma 1976; 16:882.",
"     </a>",
"    </li>",
"    <li>",
"     Injury severity score. www.trauma.org/archive/scores/iss.html (accessed on October 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/25\">",
"      Copes WS, Champion HR, Sacco WJ, et al. The Injury Severity Score revisited. J Trauma 1988; 28:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/26\">",
"      Karmy-Jones R, Copes WS, Champion HR, et al. Results of a multi-institutional outcome assessment: results of a structured peer review of TRISS-designated unexpected outcomes. J Trauma 1992; 32:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/27\">",
"      Haider AH, Crompton JG, Oyetunji T, et al. Mechanism of injury predicts case fatality and functional outcomes in pediatric trauma patients: the case for its use in trauma outcomes studies. J Pediatr Surg 2011; 46:1557.",
"     </a>",
"    </li>",
"    <li>",
"     Trauma-injury severity score. www.trauma.org/index.php/main/article/387/ (Accessed on October 16, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/29\">",
"      Schluter PJ, Nathens A, Neal ML, et al. Trauma and Injury Severity Score (TRISS) coefficients 2009 revision. J Trauma 2010; 68:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/30\">",
"      Schall LC, Potoka DA, Ford HR. A new method for estimating probability of survival in pediatric patients using revised TRISS methodology based on age-adjusted weights. J Trauma 2002; 52:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/31\">",
"      Champion HR, Copes WS, Sacco WJ, et al. A new characterization of injury severity. J Trauma 1990; 30:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/32\">",
"      Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med 1996; 24:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/33\">",
"      Castello FV, Cassano A, Gregory P, Hammond J. The Pediatric Risk of Mortality (PRISM) Score and Injury Severity Score (ISS) for predicting resource utilization and outcome of intensive care in pediatric trauma. Crit Care Med 1999; 27:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/34\">",
"      Slater A, Shann F, Pearson G, Paediatric Index of Mortality (PIM) Study Group. PIM2: a revised version of the Paediatric Index of Mortality. Intensive Care Med 2003; 29:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/35\">",
"      Brady AR, Harrison D, Black S, et al. Assessment and optimization of mortality prediction tools for admissions to pediatric intensive care in the United kingdom. Pediatrics 2006; 117:e733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/36\">",
"      Rutledge R, Osler T, Emery S, Kromhout-Schiro S. The end of the Injury Severity Score (ISS) and the Trauma and Injury Severity Score (TRISS): ICISS, an International Classification of Diseases, ninth revision-based prediction tool, outperforms both ISS and TRISS as predictors of trauma patient survival, hospital charges, and hospital length of stay. J Trauma 1998; 44:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/37\">",
"      Tepas JJ 3rd, Leaphart CL, Celso BG, et al. Risk stratification simplified: the worst injury predicts mortality for the injured children. J Trauma 2008; 65:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7367/abstract/38\">",
"      Borgman MA, Maegele M, Wade CE, et al. Pediatric trauma BIG score: predicting mortality in children after military and civilian trauma. Pediatrics 2011; 127:e892.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6459 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-DF771C1915-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7367=[""].join("\n");
var outline_f7_12_7367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Objectives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Triage decision support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Severity of illness or mortality prediction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Physiologic systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Glasgow Coma Scale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Trauma score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Revised Trauma Score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pediatric Trauma Score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Age-specific pediatric trauma score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Anatomic systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Abbreviated Injury Scale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Injury Severity Score",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anatomic profile",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H770250\">",
"      Mechanism of injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Combination systems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Trauma injury severity score (TRISS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30733506\">",
"      - Pediatric age-adjusted trauma injury severity score (PAAT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - A severity characterization of trauma (ASCOT)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Pediatric risk of mortality (PRISM III)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pediatric Index of Mortality 2 (PIM2)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - International classification injury severity score (ICISS)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30733484\">",
"      - Pediatric trauma BIG score",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREDICTIVE VALUE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6459\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6459|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/18/22822\" title=\"algorithm 1\">",
"      US 2011 trauma field triage algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6459|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/29/27102\" title=\"table 1\">",
"      Causes death children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/9/19612\" title=\"table 2\">",
"      Verification level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/37/34397\" title=\"table 3\">",
"      Trauma scoring children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2989\" title=\"table 4\">",
"      Glasgow and pediatric coma scales",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11767?source=related_link\">",
"      Overview of pediatric injury prevention: Epidemiology; history; application",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12106?source=related_link\">",
"      Prevention of falls in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_12_7368="Rosacea papules";
var content_f7_12_7368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67890%7EDERM%2F78747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67890%7EDERM%2F78747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous papules are present on the cheek.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory papules and pustules are present on the nose and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7368=[""].join("\n");
var outline_f7_12_7368=null;
var title_f7_12_7369="Overview of polyneuropathy";
var content_f7_12_7369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of polyneuropathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7369/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7369/contributors\">",
"     Seward B Rutkove, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7369/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7369/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/12/7369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms \"polyneuropathy,\" \"peripheral neuropathy,\" and \"neuropathy\" are frequently used interchangeably, but are distinct. Polyneuropathy is a specific term that refers to a generalized, relatively homogeneous process affecting many peripheral nerves, with the distal nerves usually affected most prominently. Peripheral neuropathy is a less precise term that is frequently used synonymously with polyneuropathy, but can also refer to any disorder of the peripheral nervous system including radiculopathies and mononeuropathies. Neuropathy, which again is frequently used synonymously with peripheral neuropathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polyneuropathy, can refer even more generally to disorders of the central and peripheral nervous system.",
"   </p>",
"   <p>",
"    The polyneuropathies must be distinguished from other diseases of the peripheral nervous system, including the mononeuropathies and mononeuropathy multiplex (multifocal neuropathy), and from some disorders of the central nervous system.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mononeuropathy refers to focal involvement of a single nerve, usually due to a local cause such as trauma, compression, or entrapment. Carpal tunnel syndrome is a common example of a mononeuropathy.",
"     </li>",
"     <li>",
"      Mononeuropathy multiplex refers to simultaneous or sequential involvement of noncontiguous nerve trunks. Used loosely, this term can refer to multiple compressive mononeuropathies. However, in its more specific meaning, it identifies multiple nerve infarcts due to a systemic vasculitic process that affects the vasa nervorum. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=see_link\">",
"       \"Clinical manifestations of vasculitic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diseases of the central nervous system such as a brain tumor, stroke, or spinal cord lesion occasionally present with symptoms that are difficult to distinguish from polyneuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=see_link\">",
"       \"Differential diagnosis of peripheral nerve and muscle disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review a general approach to polyneuropathy. Specific polyneuropathies are discussed in more detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiologic data on polyneuropathy are relatively limited, in part because the disease is remarkably variable in its severity, etiology, and even pathology within a population. Defining a group with polyneuropathy requires multiple assumptions and restrictive definitions.",
"   </p>",
"   <p>",
"    In one study, 4191 subjects ages 55 and older from two regions of Italy were screened by their general practitioner for symptoms of possible polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/1\">",
"     1",
"    </a>",
"    ]. Suggestive symptoms were present in 734, each of whom was subsequently examined by a neurologist for the presence of symptoms associated with bilateral impairment of at least two of the following: strength; sensation; or deep tendon reflexes. Possible (one abnormality) and probable (two abnormalities) polyneuropathy were diagnosed in 307 (7 percent) and 151 (4 percent) patients, respectively. The prevalence of polyneuropathy among patients with no recognized exposure to diseases or neurotoxic agents was 2 percent; among patients with one or two risk factors the prevalence was 12 and 17 percent, respectively. Diabetes mellitus was the most common risk factor, present in 44 percent of the patients with polyneuropathy. The next most common risk factors were alcoholism, non-alcoholic liver disease, and malignancy.",
"   </p>",
"   <p>",
"    In a population-based study from India, 2 percent of patients interviewed met the criteria for peripheral neuropathy, but this included patients with polyneuropathy, entrapment neuropathies, and peripheral nerve disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/2\">",
"     2",
"    </a>",
"    ]. A third study from Sicily found that 7 percent of the population responded positively to screening questions for polyneuropathy; diabetic neuropathy was diagnosed in 0.3 percent of the population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More comprehensive data are available regarding the frequency of specific types of polyneuropathy or those with specific causes, such as diabetic polyneuropathy or inflammatory demyelinating polyneuropathy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A natural history study following patients with type 2 diabetes mellitus noted a baseline prevalence of polyneuropathy of 8 percent compared with a control population in whom 2 percent of patients were affected [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/4\">",
"       4",
"      </a>",
"      ]. After 10 years, the number of patients who had nerve conduction abnormalities consistent with polyneuropathy reached 42 percent in the diabetic population versus 6 percent in controls. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=see_link\">",
"       \"Epidemiology and classification of diabetic neuropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of patients with clinical AIDS, 12 percent had evidence of a polyneuropathy, the majority of who were affected with a distal symmetric axonal neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/5\">",
"       5",
"      </a>",
"      ]. Inflammatory polyneuropathies, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and mononeuritis multiplex have also been described, often in patients with more recent onset of HIV infection.",
"     </li>",
"     <li>",
"      The prevalence of the Charcot-Marie-Tooth diseases, a group of hereditary polyneuropathies characterized by some common clinical features, varies significantly in different countries, from a low of 8 per 100,000 population in Libya to a high of 41 per 100,000 in Norway [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"       \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amyloid polyneuropathy, another common inherited polyneuropathy that presents in later life with progressive pain and sensory loss, also has a variable frequency [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. It is especially common in Sweden where the gene prevalence is 1500 per 100,000, although the frequency of the disorder is only 31 per 100,000 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The prevalence of Guillain-Barr&eacute; syndrome in most studies ranges from 0.4 to 1.7 per 100,000 population with a relatively even distribution throughout the world [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/10\">",
"       10",
"      </a>",
"      ]. Guillain-Barr&eacute; syndrome has been linked in some cases to preceding Campylobacter jejuni infection; the incidence may be much higher in areas of the world such as northern China where this is a common pathogen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link\">",
"       \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The prevalence of CIDP, like most axonal polyneuropathies, is not well studied, but is estimated to be 0.8 to 3.6 per 100,000. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=see_link&amp;anchor=H5#H5\">",
"       \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyneuropathy has a wide variety of causes, ranging from the common, such as diabetes mellitus, alcohol abuse, and HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/11\">",
"     11",
"    </a>",
"    ], to the rare, such as some unusual forms of Charcot-Marie-Tooth (CMT) disease. It often occurs as a side effect of medication or as a manifestation of systemic disease. The rate of progression of the polyneuropathy in conjunction with its character (axonal or demyelinating) can help identify its etiology (",
"    <a class=\"graphic graphic_table graphicRef54853 graphicRef69751 graphicRef58391 \" href=\"UTD.htm?4/48/4867\">",
"     table 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The peripheral nerves are susceptible to a variety of toxic, inflammatory, hereditary, infectious, and parainfectious factors that can impair their health and function, leading to the clinical disorder of polyneuropathy. Unfortunately, there are no simple rules to apply that can reliably distinguish the type of polyneuropathy (eg, demyelinating versus axonal, chronic versus acute, sensory versus motor) produced by these disease categories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6425345\">",
"    <span class=\"h2\">",
"     Diabetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic polyneuropathy is generally considered predominantly axonal; however, variable degrees of demyelination are often present, at least electrophysiologically. The mechanism underlying the development of diabetic neuropathy is extremely complex and likely relates to inflammatory, metabolic, and ischemic effects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"     \"Pathogenesis and prevention of diabetic polyneuropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93179184\">",
"    <span class=\"h2\">",
"     Other systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other systemic diseases generally also cause predominantly axonal polyneuropathies. Examples of these include the polyneuropathies associated with longstanding human immunodeficiency virus (HIV) infection, critical illness, amyloidosis, hypothyroidism, vitamin deficiencies, and Lyme disease. However, some important exceptions exist. As an example, polyneuropathy associated with monoclonal gammopathies is often demyelinating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93179304\">",
"    <span class=\"h2\">",
"     Autoimmune",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most acute autoimmune neuropathies, namely Guillain-Barr&eacute; syndrome, are predominantly demyelinating, and a variety of clinical and experimental data have implicated both humoral factors and cell-mediated immune phenomena, which damage myelin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the myelin-producing Schwann cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, axonal forms of this disease also exist. For example, one unusual but well-described variant of Guillain-Barr&eacute; syndrome is that of acute motor axonal polyneuropathy (AMAN). In this disorder, primary invasion of axons by inflammatory cells has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6425488\">",
"    <span class=\"h2\">",
"     Toxic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many toxic neuropathies, such as those due to alcohol, chemotherapy exposure, or most heavy metals, produce a predominantly axonal disorder that can be acute, subacute, or chronic, depending on the level and severity of the exposure. Nonetheless, it is incorrect to simply classify all toxic neuropathies as axonal, since many exceptions exist. As an example, n-hexane exposure leads to neuropathy that has a substantial demyelinating component [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6425359\">",
"    <span class=\"h2\">",
"     Hereditary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common forms of hereditary neuropathy, namely CMT types 1A, 1B, and X-linked, are all predominantly demyelinating in nature, although substantial coexistent axonal loss is usually also identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other rare hereditary diseases that cause predominantly demyelinating polyneuropathies include those secondary to metabolic diseases of childhood, such as Krabbe's disease, metachromatic leukodystrophy, and adrenoleukodystrophy. In contrast to these, some hereditary polyneuropathies can have an axonal pattern, including Charcot-Marie-Tooth Type II and neuropathies associated with mitochondrial disorders such as NARP syndrome (neuropathy, ataxia, and retinitis pigmentosa).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6425387\">",
"    <span class=\"h2\">",
"     Environmental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors can also impact nerve health in substantial ways. Neuropathies associated with vibration-induced nerve damage, prolonged cold exposure, or hypoxemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/14\">",
"     14",
"    </a>",
"    ] have been well described. These disorders are mainly axonal in nature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93179221\">",
"    <span class=\"h2\">",
"     Idiopathic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although population-based data are lacking, no specific cause is identified in up to one-quarter of patients with polyneuropathy at referral centers despite extensive investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. A variety of terms have been employed to describe this disorder, including chronic idiopathic axonal polyneuropathy (CIAP), chronic sensory polyneuropathy, chronic polyneuropathy of undetermined cause, unclassified peripheral neuropathy, and idiopathic neuropathy. Most such cases present in those &ge;50 years old and progress slowly over months to years. The symptoms are typically sensory, involving paresthesia, numbness or pain. Electrodiagnostic studies show a primarily axonal polyneuropathy. Proposed but unproven causes include impaired glucose tolerance, hypertension, dyslipidemia, and increased oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyneuropathy is typically characterized by symmetric distal sensory loss, burning, or weakness. Patients with very mild or asymptomatic polyneuropathy occasionally are identified on detailed sensory examination of the lower extremities. Alternatively, a patient may undergo electrodiagnostic testing for an unrelated problem, such as carpal tunnel syndrome, and mild abnormalities suggestive of polyneuropathy are identified. More advanced cases, however, typically present with symptoms suggestive of peripheral nerve disease, which may or may not be supported by findings on physical examination (",
"    <a class=\"graphic graphic_table graphicRef73819 graphicRef50878 graphicRef62629 \" href=\"UTD.htm?26/0/26624\">",
"     table 2A-C",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of patients with polyneuropathy varies significantly depending upon the underlying pathophysiology.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic axonal polyneuropathies (eg, due to diabetes mellitus or uremia) are by far the most common of the polyneuropathies. Injury tends to be related to axon length; thus, longer axons are affected first, resulting in symptoms that begin in the lower extremities. Sensory symptoms usually precede motor symptoms. Patients typically present with slowly progressive sensory loss and dysesthesias such as numbness, a burning sensation and pain in the feet, and mild gait abnormalities. As the syndrome progresses, mild weakness of the lower legs and hand symptoms may begin, resulting in the classic \"stocking and glove\" distribution of sensory loss. The numbness may continue to extend proximally in severe cases, affecting the intercostal nerves (the next longest nerve fibers after the arms), and causing sensory loss over the sternum. The top of the head may be affected with further progression.",
"     </li>",
"     <li>",
"      In acute axonal polyneuropathies, such as that produced by toxic exposures or porphyria, patients may present with similar but much more fulminant symptoms. Pain is often a predominant component, although it can be distinctly absent. The polyneuropathy tends to worsen over two to three weeks, plateau, and then recover over months.",
"     </li>",
"     <li>",
"      In patients with acute demyelinating polyneuropathies, primarily Guillain-Barr&eacute; syndrome (GBS), the presentation is often quite distinct from that of most axonal polyneuropathies. GBS tends to affect predominantly motor nerve fibers; thus, weakness rather than sensory loss typically is one of the earliest signs of the disease. Eventually, however, most patients will complain of some dysesthesias distally in the legs or arms. Gait difficulties or hand clumsiness secondary to reduced proprioception are also common complaints.",
"     </li>",
"     <li>",
"      Weakness and generalized sensory loss are often present simultaneously in patients with chronic inflammatory demyelinating polyneuropathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=see_link\">",
"       \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hereditary polyneuropathies generally do not complain of positive symptoms such as paresthesias or pain. Often neither patients nor their families appreciate marked neurologic deficits or atrophy since the progression of the disease is slow and insidious [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The history is important for distinguishing between polyneuropathy and mononeuropathy multiplex. Occasionally patients with the former will have symptoms that begin in one foot shortly before the other or are more pronounced in one foot. Mononeuropathy multiplex, in its acute form, usually presents with multiple mononeuropathies with involvement of entirely unrelated nerves, such as the median nerve in the arm and the sciatic nerve in the leg. However, patients may occasionally present with more symmetric sensory and motor symptoms affecting both legs that can be difficult to differentiate on clinical grounds from a severe subacute polyneuropathy. On detailed examination, relative preservation of one nerve (eg, posterior tibial) compared with another (eg, peroneal) may be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities on physical examination are similarly dependent upon the type of polyneuropathy (axonal versus demyelinating) and which classes of nerve fibers are most involved (motor versus sensory). Causes of painful sensory polyneuropathy are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef74991 \" href=\"UTD.htm?10/42/10925\">",
"     table 3",
"    </a>",
"    ). In patients with an axonal polyneuropathy, motor examination may disclose wasting of the intrinsic muscles of the feet or lower leg; similar findings are evident in the hands in more severe cases. Distal loss of sensation to pin prick, light touch, vibration, cold, and proprioception may also occur. Reflexes become hypoactive or absent distally, usually at the ankles initially.",
"   </p>",
"   <p>",
"    In contrast, generalized weakness is the rule in patients with symptoms of a more fulminant polyneuropathy secondary to demyelination. Distal muscles are predominantly affected, although weakness may affect proximal muscles to a greater extent in some individuals. Sensation is also reduced; large myelinated fibers are most damaged, resulting in abnormalities of vibratory testing and proprioception that are often out of proportion to loss of pin prick or temperature sensation. Reflexes are reduced diffusely and are often absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic axonal polyneuropathies generally experience a slow progression of disease over a period of years. As examples, in patients with diabetic polyneuropathy or elderly individuals with an idiopathic axonal polyneuropathy, sensory loss will slowly ascend and increase in severity in the legs before the hands become affected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"     \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"    </a>",
"    .) In patients with axonal polyneuropathy secondary to toxins, such as alcoholic polyneuropathy, exacerbations will follow increasing exposure to the pathogen. When a one-time event has occurred, such as axonal polyneuropathy secondary to critical illness, gradual but incomplete recovery in distal sensation and strength is the rule, often over a period of many months or years.",
"   </p>",
"   <p>",
"    The course of inflammatory demyelinating polyneuropathy is extremely variable. In patients with Guillain-Barr&eacute; syndrome, a two- to six-week period of decline is followed by stabilization and eventual improvement over several months; recovery generally depends upon the initial illness severity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=see_link\">",
"     \"Overview of Guillain-Barr&eacute; syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with chronic inflammatory demyelinating polyneuropathy, exacerbations may be followed by periods of stability in some, while in others there is a steady prolonged decline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17385?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with congenital demyelinating polyneuropathy, such as Charcot-Marie-Tooth disease, also have a variable course, even between family members with the disease. Some patients may first present in childhood, while others not until they are well into the seventh or eighth decade of life. After presentation, however, a very slow but inevitable progression of symptoms will occur. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=see_link\">",
"     \"Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously mentioned, diseases of the central nervous system can be difficult to distinguish from polyneuropathy. As an example, progressive numbness and weakness in the lower extremities may be due to a spinal cord process or polyneuropathy. Furthermore, acute myopathy, neuromuscular junction disease, or a central process may mimic Guillain-Barr&eacute; syndrome or chronic inflammatory demyelinating polyneuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=see_link\">",
"     \"Differential diagnosis of peripheral nerve and muscle disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of issues to consider when evaluating patients who present with symptoms consistent with polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/11,18,19\">",
"     11,18,19",
"    </a>",
"    ]. Extensive diagnostic testing is probably not necessary in a patient with mild symptoms who has a known underlying reason (eg, diabetes mellitus or alcohol abuse). On the other hand, a diagnostic evaluation is warranted in patients with no clear etiology or in whom symptoms are severe or rapidly progressive. In addition to the history of the neuropathy itself, the patient should be asked about recent viral illnesses, other systemic symptoms, new medications, exposures to solvents, heavy metals, or other potential toxins, alcohol use, and a family history of neurologic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case definition of distal symmetric polyneuropathy has been developed by an expert panel with representatives from the American Academy of Neurology (AAN), the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM), and the American Academy of Physical Medicine and Rehabilitation (AAPM&amp;R) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/20\">",
"     20",
"    </a>",
"    ]. While the definition was developed primarily for research purposes, it may aid clinicians by providing diagnostic criteria with a relatively high sensitivity and specificity.",
"   </p>",
"   <p>",
"    The expert panel assessed the diagnostic accuracy of neuropathic symptoms, neurologic signs (decreased or absent ankle reflexes, decreased distal sensation, distal muscle weakness or atrophy), and nerve conduction study (NCS) findings based on evidence from 12 high-quality studies. Diabetic peripheral neuropathy was the focus of most of these studies. The following observations were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms alone have a relatively poor diagnostic accuracy. Multiple neuropathic symptoms are more accurate than single symptoms.",
"     </li>",
"     <li>",
"      Signs are better predictors of polyneuropathy than symptoms and should be weighted more heavily. A single abnormality on examination is less sensitive than multiple abnormalities. Therefore, an examination for polyneuropathy should look for a combination of signs.",
"     </li>",
"     <li>",
"      Abnormal electrodiagnostic studies provide a higher level of specificity to the case definition, but they should not be used alone to make the diagnosis. Abnormal NCS are the most informative part of the electrodiagnostic evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A set of case definitions was rank ordered by estimated likelihood of distal symmetric polyneuropathy (",
"    <a class=\"graphic graphic_table graphicRef53720 \" href=\"UTD.htm?14/58/15277\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/20\">",
"     20",
"    </a>",
"    ]. The highest likelihood of polyneuropathy occurred when a combination of multiple symptoms and signs were accompanied by abnormal electrodiagnostic studies. A modest likelihood of polyneuropathy occurred when a combination of multiple symptoms and signs were present but electrodiagnostic studies were not available. A lower likelihood of polyneuropathy occurred when electrodiagnostic studies and signs were discordant.",
"   </p>",
"   <p>",
"    The expert panel found insufficient evidence to provide an adequate definition for isolated or pure small-fiber polyneuropathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Electrodiagnostic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest electrodiagnostic testing with electromyography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    nerve conduction studies",
"    <span class=\"nowrap\">",
"     (EMG/NCS)",
"    </span>",
"    as the initial diagnostic procedure for patients with suspected polyneuropathy when there is no clear etiology or when symptoms are severe or rapidly progressive (",
"    <a class=\"graphic graphic_algorithm graphicRef77479 \" href=\"UTD.htm?42/63/44018\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=see_link\">",
"     \"Overview of electromyography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrodiagnostic studies can determine if the disorder is due to a primary nerve (neuropathy) or muscle disorder (myopathy). These tests also can identify whether the patient's symptoms are secondary to a polyneuropathy or another peripheral nerve disorder (eg, polyradiculopathy from lumbar stenosis); if it is a polyneuropathy,",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    will reveal whether it is axonal or demyelinating in character. The clinical examination alone generally cannot make the latter distinction.",
"   </p>",
"   <p>",
"    Electrodiagnostic features of demyelinating disorders include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Slow nerve conduction velocity",
"     </li>",
"     <li>",
"      Dispersion of evoked compound action potentials",
"     </li>",
"     <li>",
"      Conduction block (decreased amplitude of muscle compound action potentials on proximal compared with distal nerve stimulation)",
"     </li>",
"     <li>",
"      Marked prolongation of distal latencies",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, axonal neuropathies are characterized by a reduced amplitude of evoked compound action potentials with relative preservation of the nerve conduction velocity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend selective use of laboratory tests in patients with polyneuropathy, based upon the history and the results of electrodiagnostic tests (",
"    <a class=\"graphic graphic_table graphicRef64055 \" href=\"UTD.htm?31/20/32076\">",
"     table 5",
"    </a>",
"    ). In practice, this means that most blood tests should be deferred until the results of electromyography and nerve conduction studies testing are known.",
"   </p>",
"   <p>",
"    One clear distinction that can be made by clinical neurophysiology is whether a neuropathy is due to axon loss or demyelination. As an example, thyroid function studies are unlikely to be useful if the neuropathy has prominent demyelinating features. Thus, instead of obtaining a laboratory \"screen\" for neuropathy, specific tests should be ordered based upon the pathophysiology of the underlying process (",
"    <a class=\"graphic graphic_table graphicRef64055 \" href=\"UTD.htm?31/20/32076\">",
"     table 5",
"    </a>",
"    ). This approach is more cost-effective and less confusing than ordering multiple unneeded diagnostic tests.",
"   </p>",
"   <p>",
"    In patients with distal symmetric polyneuropathy who are not initially evaluated with nerve conduction studies, the laboratory tests with the highest yield for detecting abnormalities are blood glucose, serum B12 level with methylmalonic acid (with or without homocysteine), and serum protein electrophoresis (",
"    <a class=\"graphic graphic_table graphicRef64055 \" href=\"UTD.htm?31/20/32076\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/21\">",
"     21",
"    </a>",
"    ]. This observation does not imply, however, that this screening approach is superior to choosing appropriate blood tests after clinical neurophysiologic evaluation has been performed.",
"   </p>",
"   <p>",
"    Additional testing for select patients may include lumbar puncture, genetic testing, and muscle or nerve biopsy. As an example, a lumbar puncture is helpful in identifying patients with inflammatory demyelinating polyneuropathies, as most of these disorders have a radicular component which produces a marked increase in spinal fluid protein with minimal elevation in cerebrospinal fluid white cells (albuminocytologic dissociation).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nerve biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nerve biopsy is occasionally useful for diagnosing the underlying etiology of polyneuropathy. Nerve biopsy generally is reserved for patients in whom it is difficult to define whether the process is predominantly axonal or demyelinating. Identifying demyelination with associated inflammation in these individuals may help guide treatment (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Management'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Pathologic study of nerve is sometimes helpful for picking up infiltrative diseases such as amyloid neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/7\">",
"     7",
"    </a>",
"    ], infectious diseases such as leprosy, and inflammatory neuropathies such as chronic inflammatory demyelinating polyneuropathy (CIDP), mononeuropathy multiplex due to vasculitis, and sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/22\">",
"     22",
"    </a>",
"    ]. Clinically, all of these entities are characterized by some degree of asymmetry or focality. Nerve biopsy is also useful in patients with symptoms that suggest involvement primarily of small fibers (eg, painful polyneuropathies affecting pin and temperature sensation with relatively normal electrophysiology). As previously mentioned,",
"    <span class=\"nowrap\">",
"     EMG/NCS",
"    </span>",
"    cannot effectively evaluate these neurons.",
"   </p>",
"   <p>",
"    Nerve biopsy is of low yield and should generally be avoided in patients with subacute or chronic distal symmetric polyneuropathies. The literature pertaining to this issue is sparse. A systematic review from the AAN, the AANEM, and the AAPM&amp;R found no evidence to support or refute the role of nerve biopsy in the evaluation of distal symmetric polyneuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sural nerve at the ankle is the preferred site for cutaneous nerve biopsy. Rarely, other nerves including the superficial radial, saphenous, or intermediate cutaneous nerve of the thigh can be biopsied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidermal skin biopsy is an especially useful test in the diagnosis of polyneuropathy that predominantly affects small, unmyelinated nerve fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Typical symptoms of small fiber neuropathy are distal burning, pain, numbness, and paresthesias.",
"   </p>",
"   <p>",
"    In disorders affecting mainly small, unmyelinated nerve fibers, standard electrophysiologic testing is often normal, and sural nerve biopsy may be normal or only minimally abnormal.",
"   </p>",
"   <p>",
"    The test is performed by removing a very small piece of skin just proximal to the ankle; the wound is allowed to heal by secondary intention. Special stains are then applied to the skin tissue and the number and morphology of axons within the epidermis evaluated, either by qualitative assessment, or by careful counting to determine intraepidermal nerve fiber density [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/27\">",
"     27",
"    </a>",
"    ]. These values are compared with age-dependent normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review and practice parameter published in 2009 by the AAN, the AANEM, and the AAPM&amp;R concluded that intraepidermal nerve fiber density determination, using anti-protein gene product 9.5 immunohistochemistry, is a validated and reproducible marker of small fiber sensory neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the relative simplicity of the technique and its ability to provide quantitative data, the test is also likely to be useful in following disease progression or response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Autonomic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomic testing can be useful for evaluating patients with small fiber sensory neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/23\">",
"     23",
"    </a>",
"    ]. The composite autonomic scoring scale (CASS), which includes measurements of orthostatic blood pressure, the quantitative sudomotor axon reflex test, heart rate response to tilt, heart rate variability with deep breathing, and changes in blood pressure with the Valsalva maneuver, appears to provide a useful measure of autonomic function and can help support a diagnosis of small fiber sensory neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Quantitative sensory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative sensory testing measures the degree of sensory loss to various modalities, including temperature and vibration. It is helpful in some patients to identify subtle abnormalities and demonstrate the progression or stability of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two separate aspects to the treatment of polyneuropathy: treatment of the underlying disease; and alleviation of symptoms related to the illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Treatment of the underlying process",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-specific treatment of polyneuropathy obviously depends upon the underlying process. Nevertheless, some generalizations can be made for treating the axonal and demyelinating polyneuropathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Axonal polyneuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reducing exposure to endogenous or exogenous toxins that may be causing the polyneuropathy is the single most important step in treating and preventing the progression of axonal polyneuropathies. As an example, in patients with axonal polyneuropathy secondary to alcohol or drugs, avoidance of the offending agent is extremely important.",
"   </p>",
"   <p>",
"    In patients with diabetes mellitus, tight control of blood glucose may help maintain nerve function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of diabetic neuropathy\", section on 'Glycemic control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similarly, in patients with a polyneuropathy secondary to one of the rheumatic diseases, treatment of the underlying illness is important to at least halt the progression, if not to reverse symptoms. Thyroid replacement typically ameliorates the symptoms of hypothyroid polyneuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=see_link&amp;anchor=H17#H17\">",
"     \"Neurologic manifestations of hypothyroidism\", section on 'Peripheral neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Demyelinating polyneuropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike axonal polyneuropathy, many treatment options are available for most acquired demyelinating polyneuropathies, such as chronic inflammatory demyelinating polyneuropathy (CIDP) or Guillain-Barr&eacute; syndrome (GBS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17385?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=see_link\">",
"     \"Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of the underlying disease is most important in patients with CIDP secondary to a lymphoproliferative disorder such as multiple myeloma or Waldenstr&ouml;m's macroglobulinemia. The mainstays of treatment for CIDP are intravenous immune globulin, glucocorticoids, and plasma exchange. These treatments appear to be equally effective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17385?source=see_link\">",
"     \"Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some disorders respond better than others; patients with IgG and IgA monoclonal gammopathies of undetermined significance tend to respond better than patients with IgM [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of symptoms and prevention of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     Gabapentin",
"    </a>",
"    substantially reduces pain associated with polyneuropathy and is generally well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7369/abstract/30\">",
"     30",
"    </a>",
"    ]. Tricyclic antidepressants have been utilized for many years for this condition and are generally considered effective.",
"   </p>",
"   <p>",
"    Many other medications have also been tried in the treatment of painful polyneuropathy with varying success, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/9/10389?source=see_link\">",
"     mexiletine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/46/18150?source=see_link\">",
"     dextromethorphan",
"    </a>",
"    . Unfortunately, there are no well-executed studies comparing the effectiveness of these drugs for this condition, thereby limiting the ability of practitioners to make evidence- based decisions.",
"   </p>",
"   <p>",
"    For the treatment of painful diabetic polyneuropathy, measures include glycemic control, antidepressant drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , other tricyclics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    ), anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    ), and alpha-lipoic acid. These are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of diabetic neuropathy\", section on 'Pain control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One approach for patients who have pain associated with polyneuropathy is to start treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    at a dose of 100 to 300 mg three times a day, and then gradually increase up to a total daily dose of 4000 mg or more as needed, as long as side effects (eg drowsiness, peripheral edema) are not evident. Tricyclic antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39144?source=see_link\">",
"     desipramine",
"    </a>",
"    10 to 50 mg at night) may also be useful, but are often not as well tolerated as gabapentin.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    or other anticonvulsants may be helpful if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and tricyclics are ineffective or poorly tolerated. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/62/37864?source=see_link\">",
"     duloxetine",
"    </a>",
"    is also a reasonable consideration at this point, regardless of the etiology of the polyneuropathy. Duloxetine has the potential advantage of having antidepressant effects, and thus may be useful in patients with pain and depression.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    may be especially useful for patients who are obese, since it has the often-beneficial side effects of reduced appetite and weight loss. However, this drug has the prominent untoward effect of drowsiness.",
"   </p>",
"   <p>",
"    Simultaneous treatment with drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , NSAIDs, or low-dose narcotics may be necessary in some patients for occasional \"breakthrough pain.\"",
"   </p>",
"   <p>",
"    Physical therapy evaluation is important in patients with significant weakness. Appropriate use of ankle-foot orthoses, splints, and walking assistance devices can significantly improve lifestyle in the face of significant disability.",
"   </p>",
"   <p>",
"    Patients with distal polyneuropathy are at increased risk for developing foot ulcers; proper foot and nail care is especially important in this population. Regular visits to a podiatrist can also help prevent problems. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"     \"Evaluation of the diabetic foot\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H120471100\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polyneuropathy is a specific term that refers to a generalized, relatively homogeneous process affecting many peripheral nerves, with the distal nerves usually affected most prominently. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polyneuropathy has a wide variety of causes, ranging from the common, such as diabetes mellitus, alcohol abuse, and HIV infection, to the rare. It often occurs as a side effect of medication or as a manifestation of systemic disease, but many cases are idiopathic. The rate of progression of the polyneuropathy in conjunction with its character (axonal or demyelinating) can help identify its etiology (",
"      <a class=\"graphic graphic_table graphicRef54853 graphicRef69751 graphicRef58391 \" href=\"UTD.htm?4/48/4867\">",
"       table 1A-C",
"      </a>",
"      ).The peripheral nerves are susceptible to a variety of toxic, inflammatory, hereditary, infectious, and parainfectious factors that can impair their health and function, leading to the clinical disorder of polyneuropathy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polyneuropathy is typically characterized by symmetric distal sensory loss, burning, or weakness. The presentation of patients with polyneuropathy varies significantly depending upon the underlying pathophysiology. Abnormalities on physical examination are similarly dependent upon the type of polyneuropathy (axonal versus demyelinating) and which classes of nerve fibers are most involved (motor versus sensory). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Electromyography/nerve",
"      </span>",
"      conduction studies",
"      <span class=\"nowrap\">",
"       (EMG/NCS)",
"      </span>",
"      should be the initial diagnostic study in all patients with symptoms and signs of polyneuropathy (",
"      <a class=\"graphic graphic_algorithm graphicRef77479 \" href=\"UTD.htm?42/63/44018\">",
"       algorithm 1",
"      </a>",
"      ). We recommend selective use of laboratory tests in patients with polyneuropathy, based upon the history and the results of electrodiagnostic tests (",
"      <a class=\"graphic graphic_table graphicRef64055 \" href=\"UTD.htm?31/20/32076\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two separate aspects to the treatment of polyneuropathy: treatment of the underlying disease; and alleviation of symptoms related to the illness. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/1\">",
"      Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG). Neurology 1995; 45:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/2\">",
"      Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology 1991; 41:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/3\">",
"      Savettieri G, Rocca WA, Salemi G, et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1993; 43:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/4\">",
"      Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995; 333:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/5\">",
"      Fuller GN, Jacobs JM, Guiloff RJ. Nature and incidence of peripheral nerve syndromes in HIV infection. J Neurol Neurosurg Psychiatry 1993; 56:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/6\">",
"      Radhakrishnan K, el-Mangoush MA, Gerryo SE. Descriptive epidemiology of selected neuromuscular disorders in Benghazi, Libya. Acta Neurol Scand 1987; 75:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/7\">",
"      Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007; 36:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/8\">",
"      Plant&eacute;-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/9\">",
"      Holmgren G, Costa PM, Andersson C, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994; 31:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/10\">",
"      Alter M. The epidemiology of Guillain-Barr&eacute; syndrome. Ann Neurol 1990; 27 Suppl:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/11\">",
"      Hughes R. Investigation of peripheral neuropathy. BMJ 2010; 341:c6100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/12\">",
"      Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996; 40:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/13\">",
"      Kuwabara S, Kai MR, Nagase H, Hattori T. n-Hexane neuropathy caused by addictive inhalation: clinical and electrophysiological features. Eur Neurol 1999; 41:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/14\">",
"      Ozge A, Ati�� S, Sevim S. Subclinical peripheral neuropathy associated with chronic obstructive pulmonary disease. Electromyogr Clin Neurophysiol 2001; 41:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/15\">",
"      Gordon Smith A, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci 2006; 242:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/16\">",
"      Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981; 10:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/17\">",
"      Singer MA, Vernino SA, Wolfe GI. Idiopathic neuropathy: new paradigms, new promise. J Peripher Nerv Syst 2012; 17 Suppl 2:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/18\">",
"      Dyck PJ, Dyck PJ, Grant IA, Fealey RD. Ten steps in characterizing and diagnosing patients with peripheral neuropathy. Neurology 1996; 47:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/19\">",
"      Callaghan B, McCammon R, Kerber K, et al. Tests and expenditures in the initial evaluation of peripheral neuropathy. Arch Intern Med 2012; 172:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/20\">",
"      England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/21\">",
"      England JD, Gronseth GS, Franklin G, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/22\">",
"      England JD, Asbury AK. Peripheral neuropathy. Lancet 2004; 363:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/23\">",
"      England JD, Gronseth GS, Franklin G, et al. Practice Parameter: evaluation of distal symmetric polyneuropathy: role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009; 72:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/24\">",
"      Lauria G. Small fibre neuropathies. Curr Opin Neurol 2005; 18:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/25\">",
"      Sommer C, Lauria G. Skin biopsy in the management of peripheral neuropathy. Lancet Neurol 2007; 6:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/26\">",
"      Vlckov&aacute;-Moravcov&aacute; E, Bednar&iacute;k J, Dusek L, et al. Diagnostic validity of epidermal nerve fiber densities in painful sensory neuropathies. Muscle Nerve 2008; 37:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/27\">",
"      McCarthy BG, Hsieh ST, Stocks A, et al. Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 1995; 45:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/28\">",
"      McArthur JC, Stocks EA, Hauer P, et al. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol 1998; 55:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/29\">",
"      Dyck PJ, Low PA, Windebank AJ, et al. Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991; 325:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7369/abstract/30\">",
"      Guay DR. Update on gabapentin therapy of neuropathic pain. Consult Pharm 2003; 18:158.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5284 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7369=[""].join("\n");
var outline_f7_12_7369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H120471100\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6425345\">",
"      Diabetic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93179184\">",
"      Other systemic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93179304\">",
"      Autoimmune",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6425488\">",
"      Toxic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6425359\">",
"      Hereditary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6425387\">",
"      Environmental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93179221\">",
"      Idiopathic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Electrodiagnostic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nerve biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Autonomic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Quantitative sensory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Treatment of the underlying process",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Axonal polyneuropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Demyelinating polyneuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of symptoms and prevention of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H120471100\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5284\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5284|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?42/63/44018\" title=\"algorithm 1\">",
"      Diagnosis of polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5284|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/45/43742\" title=\"table 1A\">",
"      Polyneuropathy systemic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/47/44798\" title=\"table 1B\">",
"      Polyneuropathy drugs toxins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/59/25533\" title=\"table 1C\">",
"      Genetic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/26/37293\" title=\"table 2A\">",
"      Muscle innervation part A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/19/38205\" title=\"table 2B\">",
"      Muscle innervation part B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/37/6750\" title=\"table 2C\">",
"      Muscle innervation part C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/42/10925\" title=\"table 3\">",
"      Painful neuropathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/58/15277\" title=\"table 4\">",
"      Likelihood distal symmetric polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/20/32076\" title=\"table 5\">",
"      Lab tests in polyneuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/33/40472?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/62/17385?source=related_link\">",
"      Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=related_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22423?source=related_link\">",
"      Clinical manifestations of vasculitic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=related_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=related_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/59/35770?source=related_link\">",
"      Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36585?source=related_link\">",
"      Neurologic manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27705?source=related_link\">",
"      Overview of Guillain-Barr&eacute; syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1769?source=related_link\">",
"      Overview of electromyography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=related_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/265?source=related_link\">",
"      Treatment and prognosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=related_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_12_7370="Mitochondrial myopathies: Clinical features and diagnosis";
var content_f7_12_7370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mitochondrial myopathies: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7370/contributors\">",
"     Angela Genge, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7370/contributors\">",
"     Rami Massie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7370/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/12/7370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/12/7370/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/12/7370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondria are the cellular organelles responsible for oxidative phosphorylation, which produces energy in the form of adenosine triphosphate (ATP). This process is accomplished by the respiratory chain located in the inner mitochondrial membrane. In addition, mitochondria perform multiple other tasks, including pyruvate oxidation, the Krebs cycle, fatty acid oxidation, and amino acid metabolism, all of which take place in the mitochondrial matrix. Although an abnormality in any of these pathways could be technically designated as a mitochondrial disease, only defects in the respiratory chain that impair oxidative phosphorylation are traditionally considered to be primary mitochondrial disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12853?source=see_link\">",
"     \"Mitochondrial structure, function, and genetics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mitochondrial diseases are a group of disorders caused by pathologic dysfunction of the mitochondrial respiratory chain that present with a wide range of clinical expression. Organ systems relying most on aerobic metabolism are preferentially affected and involvement of the nervous system in general (referred to as mitochondrial encephalomyopathy) is common. When skeletal muscle is affected, either alone or with central nervous system disease, the term mitochondrial myopathy is used.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, and diagnosis of the mitochondrial myopathies are discussed in this topic review. Treatment is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2536?source=see_link\">",
"     \"Mitochondrial myopathies: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although once considered rare, accumulating evidence suggests that mitochondrial disorders are relatively common.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population-based study reviewed all pediatric health records from western Sweden from 1984 until 1999 and found that the incidence of mitochondrial encephalomyopathies in preschool aged children was 1 in 11,000 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/1\">",
"       1",
"      </a>",
"      ]. The point prevalence in children younger than 16 was 1 in 21,000. Due to the high childhood mortality of these disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/2\">",
"       2",
"      </a>",
"      ], the median survival for those with infantile onset was age 12 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/1\">",
"       1",
"      </a>",
"      ]. This explains the relatively lower point prevalence than expected for chronic diseases. The study used stringent inclusion criteria, and concluded that the results were minimum estimates of the true incidence and prevalence. All but one of the 32 children in the study had muscle involvement, suggesting that the incidence and prevalence of mitochondrial myopathies is only slightly less than that reported for mitochondrial encephalomyopathies.",
"     </li>",
"     <li>",
"      A report from northeast England of adolescents and adults (ages 16 to 65 years old) with mitochondrial disease found a point prevalence of 6.6 per 100,000 population (or 1 in 15,200 persons) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/3\">",
"       3",
"      </a>",
"      ]. The investigators estimated that this figure might represent only one-third of the true prevalence based upon under-referral. No specific figures for myopathy were reported. One-half of the patients were diagnosed with Leber hereditary optic neuropathy (LHON), a condition that usually does not have a significant degree of myopathy. In the Swedish report cited above, LHON was present in only 3 percent.",
"     </li>",
"     <li>",
"      The same group from northeast England screened 3168 neonatal cord blood samples for 10 common mtDNA point mutations and found that the prevalence of mtDNA point mutations was greater than 1 in 200 individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/4\">",
"       4",
"      </a>",
"      ]. However, some of these mutations will never be clinically expressed due to variable heteroplasmy.",
"     </li>",
"     <li>",
"      An Australian study estimated that the minimal birth prevalence of primary mitochondrial disorders was 6.2 cases per 100,000 births [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Spanish study estimated that the prevalence of mitochondrial disease in a population over 14 years of age was 5.7 per 100,000 [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/6\">",
"       6",
"      </a>",
"      ]. Electrophysiologic analysis detected signs of myopathy in 80 percent of patients examined and neuropathy in 22 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite different geographical areas and populations sampled, all four studies show grossly concordant results. Given the non-overlapping ages of disease onset between the northeast England study (after age four) and the Australian report (generally before age four), the Australian investigators extrapolated that the overall prevalence of oxidative phosphorylation defects is at least 13.1 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/5\">",
"     5",
"    </a>",
"    ]. This estimate, if accurate, indicates that primary mitochondrial disorders are the most common inherited errors of metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data also suggest that, with the exception of patients with Leber hereditary optic neuropathy, the vast majority of patients with mitochondrial disorders will display signs of myopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical expression of mitochondrial myopathies is extremely variable. Myopathy may be the sole or main sign, or merely an incidental finding associated with a multisystemic illness. The severity of these disorders ranges from asymptomatic mild proximal limb weakness to fatal infantile myopathy.",
"   </p>",
"   <p>",
"    Myopathies are ubiquitous in mitochondrial disorders, and even asymptomatic patients will typically have significant muscle pathology on biopsy. This is the result of a relatively high level of heteroplasmy and mutant DNA in a tissue (muscle) that is highly dependent on oxidative aerobic metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12853?source=see_link&amp;anchor=H4#H4\">",
"     \"Mitochondrial structure, function, and genetics\", section on 'Mitochondrial genetics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following groups illustrate the different ways mitochondrial myopathies can present clinically:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      As chronic progressive external ophthalmoplegia (with or without mild proximal muscle weakness) or Kearns-Sayre syndrome",
"     </li>",
"     <li>",
"      As an isolated myopathy with or without exercise intolerance",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      myalgia",
"     </li>",
"     <li>",
"      As a severe myopathy or encephalomyopathy of infancy and childhood",
"     </li>",
"     <li>",
"      As a predominantly multisystem disease with myopathy (eg, MELAS and MERRF)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A certain degree of overlap exists between all these entities. For instance, patients suffering from CPEO might develop mild proximal muscle weakness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise intolerance later in life. Alternatively, patients who initially have only exercise intolerance or a mild proximal myopathy can progress into external ophthalmoplegia.",
"   </p>",
"   <p>",
"    Mitochondrial myopathies can be classified according to whether the causative mutations affect mitochondrial DNA or nuclear DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef55067 \" href=\"UTD.htm?16/14/16621\">",
"     table 1",
"    </a>",
"    ). Each group can be further subdivided into mutations of genes that directly encode respiratory chain proteins and those that encode ancillary machinery (eg,",
"    <span class=\"nowrap\">",
"     transfer/ribosomal",
"    </span>",
"    RNA or proteins needed for the proper assembly or function of the respiratory chain proteins). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12853?source=see_link&amp;anchor=H13#H13\">",
"     \"Mitochondrial structure, function, and genetics\", section on 'Genetic classification of mitochondrial disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although essential for understanding the pathophysiology of these disorders (and perhaps important as a basis for future therapies), the genetic classification has limited clinical relevance at the present time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic progressive external ophthalmoplegia (CPEO) typically develop paresis of extraocular muscles along with bilateral ptosis in their thirties, although they can present at any age. The disease is slowly progressive, with the result that diplopia is usually absent or only transient. The lack of diplopia has been explained by the symmetric nature of the ophthalmoplegia, but even patients with dysconjugate gaze rarely complain of diplopia. Patients with CPEO often have a low degree of early disability, but detailed evaluation of vision will frequently uncover significant visual deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of CPEO includes myasthenia gravis, ocular myositis, thyroid associated orbitopathy, oculopharyngeal muscular dystrophy and congenital fibrosis of the extraocular muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kearns-Sayre syndrome (KSS) refers to the combination of CPEO with pigmentary retinopathy and onset before age 20. Other abnormalities have been described, including short stature, cerebellar ataxia, raised CSF protein (&gt;100",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    cardiac conduction defects or cognitive",
"    <span class=\"nowrap\">",
"     deficits/mental",
"    </span>",
"    retardation. KSS is usually more aggressive than isolated CPEO, progressing to complete ophthalmoparesis, and often to death by the fourth decade due to the associated deficits. Patients with either disorder can develop a proximal myopathy, which usually does not limit daily functioning, particularly for patients with CPEO.",
"   </p>",
"   <p>",
"    The most common causes of sporadic CPEO and KSS are large scale mutations causing deletions or duplications of mitochondrial DNA. Since the primary cause involves mitochondrial DNA, this mechanism is not consistent with Mendelian inheritance. A few transfer RNA mutations in mitochondrial DNA have also been described.",
"   </p>",
"   <p>",
"    Familial CPEO can be either autosomal dominant or autosomal recessive and is due to nuclear DNA mutations. It seems to have a higher percentage of associated abnormalities than sporadic CPEO, such as bulbar symptoms (dysphagia, dysphonia, hearing impairment), severe depression, cataracts or neuropathy.",
"   </p>",
"   <p>",
"    Autosomal dominant and autosomal recessive forms of CPEO are linked to mutations in several nuclear DNA genes, including POLG, C10orf2, RRM2B, SLC25A4, POLG2, and DGUOK, which cause defects in intergenomic signaling leading to multiple secondary mitochondrial DNA deletions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/12-15\">",
"     12-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H124912918\">",
"    <span class=\"h2\">",
"     Leber hereditary optic neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leber hereditary optic neuropathy (LHON) is a maternally inherited bilateral subacute optic neuropathy. LHON typically produces severe and permanent visual loss in young men. With the rare exceptions of two distinct mitochondrial DNA mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/16,17\">",
"     16,17",
"    </a>",
"    ], LHON is usually not associated with myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/18\">",
"     18",
"    </a>",
"    ]. LHON is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link&amp;anchor=H23#H23\">",
"     \"Hereditary neuropathies associated with generalized disorders\", section on 'Leber hereditary optic neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Isolated myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial disorders can occasionally present as an isolated proximal myopathy. Some patients with this condition are almost asymptomatic, while others can have fatigue and exercise-induced symptoms including myalgia, myoglobinuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exercise intolerance. The latter complaints are extremely common in neuromuscular clinics, and patients presenting only with exercise intolerance or myalgias can sometimes be misdiagnosed as suffering from fibromyalgia and not properly investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    From a genetic point of view, isolated mitochondrial myopathies are the most heterogeneous group of mitochondrial disorders. Genetic defects have been described mainly in individual subunit protein coding genes, including mitochondrial DNA, such as for complex I (ND1 and ND4 mutations), complex III (cytochrome b mutations) or complex IV (mutations in COXI, COXII, or COXIII), and nuclear DNA, as occurs in isolated myopathy secondary to coenzyme Q10 deficiency. Less commonly, mitochondrial DNA genetic abnormalities affecting protein synthesis as a whole (several point mutations in transfer RNA genes) have been described, as opposed to point mutation of protein coding genes noted earlier. A slowly progressive generalized myopathy has been reported uncommonly with DNA depletion secondary to TK2 gene mutations that predominantly involves axial and proximal muscles, but also affects respiratory, facial and ocular muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, a rapidly progressive and predominantly myopathic presentation with DNA depletion secondary to TK2 mutations has been described in severe mitochondrial DNA depletion of infancy and childhood (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Severe encephalomyopathy of infancy or childhood'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Unfortunately, the yield of muscle biopsy with patients presenting with complaints of muscle pain and a normal neurologic examination is quite low. This point is illustrated by a retrospective study of 240 patients who had isolated muscle pain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/21\">",
"     21",
"    </a>",
"    ]. A clear diagnosis of mitochondrial disease was confirmed in only one case (&lt;1 percent). Factors that may increase the yield of finding any type of underlying myopathy include a seven-fold or more increase in serum creatinine kinase or myalgias only associated with exercise. The clinician must be very careful to look for any clue of systemic involvement such as diabetes or sensory deficits (hearing loss, abnormal EMG). A history of milder myopathic abnormalities, such as poor performance in sports or older age for reaching major motor milestones, is also supportive of the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Severe encephalomyopathy of infancy or childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial disorders presenting in infancy and early childhood have a variable expression, but myopathy is a frequent manifestation.",
"   </p>",
"   <p>",
"    In a retrospective study of primary mitochondrial disorders presenting in 32 neonates between 1975 and 2006, the most common presentation of mitochondrial disease was an encephalomyopathic form (isolated or combined symptoms and signs of encephalopathy, seizures, hypotonia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ophthalmopathy), which was noted in 17 patients (53 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/22\">",
"     22",
"    </a>",
"    ]. Other presentations included a hepato-intestinal form in 25 percent, a cardiac form manifesting mainly as early fatal cardiomyopathy in 16 percent, and Barth syndrome (X-linked cardiomyopathy, mitochondrial myopathy and cyclic neutropenia) in 6 percent. Prognosis was poor. Overall, 13 patients died in the neonatal period, another 15 died later, two were lost to follow-up, and two survived.",
"   </p>",
"   <p>",
"    In its most flagrant form, severe encephalomyopathy of infancy or childhood presents at birth with marked hypotonia, respiratory muscle weakness requiring ventilatory support, and feeding difficulty [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Affected infants usually die before reaching one year of age, leading to the term \"lethal infantile mitochondrial disease\" [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/24\">",
"     24",
"    </a>",
"    ]. They may have associated brain, heart, liver or kidney involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/25-29\">",
"     25-29",
"    </a>",
"    ]. The cause is usually a mitochondrial DNA depletion syndrome secondary to mutations in the thymidine kinase 2 (TK2) or succinyl-CoA synthetase ligase 2 (SUCLA2) genes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Some children have associated severe renal failure resulting from generalized proximal tubular dysfunction (ie, the Fanconi syndrome) and have a deficiency in complex III [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Coenzyme Q10 deficiency can also cause a rapidly fatal encephalomyopathy of infancy with nephrotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=see_link\">",
"     \"Renal involvement in the mitochondrial cytopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mutations in the TK2 gene or SUCLA2 gene can also present with a phenotype of childhood onset reminiscent of muscular dystrophy. Persistent increased serum creatinine kinase as well as membrane abnormalities similar to Duchenne muscular dystrophy further complicate differentiation of this entity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, an infantile presentation with a severe pure myopathy, lacking multisystem involvement, has been described. A small proportion of these children with COX subunit deficiency improves spontaneously over the following two years and is often normal by two or three years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/35\">",
"     35",
"    </a>",
"    ]. The molecular basis of this rare disorder is an mtDNA transfer-RNA mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Predominantly multisystem disease with myopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the hallmarks of mitochondrial disorders is multisystemic involvement. In patients with predominantly multisystem disease, there is a variable combination of central",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral nervous system involvement, ophthalmologic abnormalities, sensorineural hearing loss, gastrointestinal symptoms, cardiac, hepatic and renal disease, endocrine dysfunction, and growth failure (short stature) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/37\">",
"     37",
"    </a>",
"    ]. Affected patients are often quite disabled.",
"   </p>",
"   <p>",
"    Mitochondrial disorders that manifest as recognized clinical syndromes involving multiple organ systems include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Barth syndrome (X-linked cardiomyopathy, mitochondrial myopathy and cyclic neutropenia) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/38\">",
"       38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Growth retardation, amino aciduria, cholestasis, iron overload, lactic acidosis, and early death (GRACILE) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Leber hereditary optic neuropathy (LHON)",
"     </li>",
"     <li>",
"      Leigh syndrome (subacute necrotizing encephalomyelopathy)",
"     </li>",
"     <li>",
"      Maternally inherited deafness and diabetes (MIDD)",
"     </li>",
"     <li>",
"      Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS)",
"     </li>",
"     <li>",
"      Mitochondrial neurogastrointestinal encephalopathy (MNGIE)",
"     </li>",
"     <li>",
"      Myoclonic epilepsy with ragged red fibers (MERRF)",
"     </li>",
"     <li>",
"      Neuropathy, ataxia and retinitis pigmentosa (NARP)",
"     </li>",
"     <li>",
"      Pearson syndrome (sideroblastic anemia and pancreatic dysfunction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of these, Leigh syndrome and MELAS are the most common [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/40\">",
"     40",
"    </a>",
"    ]. Genetic abnormalities vary depending on the syndrome.",
"   </p>",
"   <p>",
"    A large proportion of patients with these multisystem disorders probably have significant muscle involvement that is never noticed or diagnosed, either because the disease is rapidly fatal or because severe disability precludes recognition of the myopathy.",
"   </p>",
"   <p>",
"    Patient with MELAS, MERRF, MNGIE, and Leigh syndrome can demonstrate significant myopathic changes on detailed evaluation. However, the myopathy in these conditions usually does not lead to significant functional impairment.",
"   </p>",
"   <p>",
"    This point is illustrated by a study that evaluated 50 patients with MELAS, specifically those with the A3243G tRNA mutation responsible for 80 percent of MELAS cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/41\">",
"     41",
"    </a>",
"    ]. One-half of the patients had evidence of a myopathy on clinical grounds alone, and up to 72 percent of biopsy specimens showed histologic abnormalities consistent with mitochondrial myopathy. Moderate limb weakness was the most common myopathic sign. Ptosis and external ophthalmoplegia were variably present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Leigh syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leigh syndrome (subacute necrotizing encephalomyelopathy) typically presents in infancy or early childhood, although late childhood and adult onset has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/42\">",
"     42",
"    </a>",
"    ]. It is characterized by developmental delay or psychomotor regression, ataxia, dystonia, external ophthalmoplegia, seizures, lactic acidosis, vomiting, and weakness.",
"   </p>",
"   <p>",
"    Some patients have myopathy and peripheral neuropathy. Brain MRI shows abnormal white matter signal in the putamen, basal ganglia, and brainstem on T2 and FLAIR sequence images. The term Leigh-like syndrome is used when atypical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    non-neurologic features (eg, diabetes, short stature, hypertrichosis, cardiomyopathy, anemia, renal failure, vomiting, or diarrhea) are present [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is generally poor, with survival generally being a matter of months after disease onset.",
"   </p>",
"   <p>",
"    The phenotype of Leigh syndrome is caused by alterations of mitochondrial metabolism from a variety of mechanisms. These include abnormalities of the pyruvate dehydrogenase complex and respiratory chain dysfunction due to either nuclear or mitochondrial DNA mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     MELAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndrome of mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS) is a maternally inherited multisystemic disorder caused by mutations of mitochondrial DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. The hallmark of this syndrome is the occurrence of stroke-like episodes that result in hemiparesis, hemianopia, or cortical blindness. Other common features include focal or generalized seizures, recurrent migraine-like headaches, vomiting, short stature, hearing loss, and muscle weakness. A multitude of transfer RNA mutations can be responsible for MELAS but 80 percent of cases are related to the A3243G mutation and 10 percent to the T3271C transfer RNA mutation.",
"   </p>",
"   <p>",
"    MELAS usually manifests in childhood after a normal early development [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/45,46,49\">",
"     45,46,49",
"    </a>",
"    ]. A relapsing-remitting course is most common, with stroke-like episodes leading to progressive neurologic dysfunction and dementia.",
"   </p>",
"   <p>",
"    The original diagnostic criteria for MELAS required stroke-like episodes before age 40 years, encephalopathy characterized by seizures or dementia, and either blood lactic acidosis or the presence of ragged red fibers in skeletal muscle biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/46,50\">",
"     46,50",
"    </a>",
"    ]. However, a broader range of phenotypes is now recognized as compatible with the diagnosis, including clinical onset after age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     MERRF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonic epilepsy with ragged red fibers (MERRF) is characterized by myoclonus, typically as the first symptom, and is associated with generalized epilepsy, ataxia, and myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/53\">",
"     53",
"    </a>",
"    ]. Additional features can include dementia, optic atrophy, bilateral deafness, peripheral neuropathy, spasticity, lipomatosis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiomyopathy with Wolff-Parkinson-White syndrome. Childhood onset after a normal early development is most common.",
"   </p>",
"   <p>",
"    MERRF is caused by mutations in mitochondrial DNA. More than 80 percent of patients suffering from MERRF harbor an A8344G point mutation in a transfer RNA gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MIDD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although phenotypic expression is variable, maternally inherited deafness and diabetes (MIDD) is characterized by both a defect in insulin secretion, which progresses to insulin dependence, and sensorineural (cochlear) hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. The mean age of onset of diabetes and hearing loss is between 30 and 40. Other abnormalities commonly associated with MIDD include macular retinal dystrophy, myopathy, cardiac disorders, gestational diabetes, renal disease, particularly focal segmental glomerular sclerosis, short stature, and gastrointestinal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study with data for 51 patients diagnosed with MIDD found myopathy in 22 (43 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/57\">",
"     57",
"    </a>",
"    ]. Myopathy typically affects proximal limbs and may be associated with exercise-induced cramps and weakness.",
"   </p>",
"   <p>",
"    MIDD is caused by a mitochondrial mutation at position A3243G in transfer RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/54\">",
"     54",
"    </a>",
"    ], the same mutation that is responsible for 80 percent of MELAS cases. Overlapping features in some patients suggest a continuum of expression for the A3243G mutation from diabetes and hearing loss alone, to MIDD, to MELAS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'MELAS'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     MNGIE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial neurogastrointestinal encephalopathy (MNGIE) is a multisystem mitochondrial disorder characterized by progressive, severe gastrointestinal dysmotility and cachexia, ptosis, ophthalmoplegia or ophthalmoparesis without diplopia, symmetric polyneuropathy, and asymptomatic leukoencephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gastrointestinal dysmotility and pseudo-obstruction of MNGIE appear to be caused by a visceral mitochondrial myopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/60\">",
"     60",
"    </a>",
"    ]. Common symptoms include early satiety, nausea, dysphagia, gastroesophageal reflux, postprandial emesis, episodic abdominal pain, abdominal distention, and diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/59\">",
"     59",
"    </a>",
"    ]. The neuropathy is predominantly demyelinating, but concurrent axonal involvement is frequent. Symptoms include paresthesia, pain, and distal weakness.",
"   </p>",
"   <p>",
"    The age of MNGIE onset, the order of symptom presentation, and the rate of disease progression are highly variable. Onset ranges from the first to the fifth decades [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/59\">",
"     59",
"    </a>",
"    ], but occurs before age 20 in 60 to 73 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/58,61,62\">",
"     58,61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term prognosis of MNGIE is poor. In one study of 35 patients, the mean age at death was 38 years (range 26 to 58 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MNGIE is a nuclear DNA disorder caused by mutations of the TYMP gene (also called ECGF1) that encodes thymidine phosphorylase, leading to secondary depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiple deletions of mitochondrial DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/61\">",
"     61",
"    </a>",
"    ]. Inheritance is autosomal recessive. In a case report, an adult patient with a phenotype similar to MNGIE but normal levels of plasma thymidine was found to have two pathogenic mutations in the RRM2B gene [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     NARP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathy, ataxia and retinitis pigmentosa (NARP) is characterized by a variable combination of developmental delay, sensory polyneuropathy, ataxia, pigmentary retinopathy, muscle weakness, epilepsy and dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/64\">",
"     64",
"    </a>",
"    ]. Late childhood or adult onset is most common.",
"   </p>",
"   <p>",
"    NARP is caused by a T8993G mutation of the mitochondrial ATPase 6 gene. The same gene is also linked with maternally inherited Leigh syndrome. Some evidence suggests that the Leigh syndrome phenotype is associated with a higher T8993G tissue mutation load than the NARP phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Pearson syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pearson syndrome (sideroblastic anemia and pancreatic dysfunction) is a congenital multisystem disorder characterized by severe anemia, ring sideroblasts in the bone marrow, neutropenia, thrombocytopenia, and exocrine pancreatic insufficiency. It is caused by mitochondrial DNA deletions ranging from 2 to 10 kilobases in size [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/67\">",
"     67",
"    </a>",
"    ]. The deletions are typically more abundant in blood than in other tissues.",
"   </p>",
"   <p>",
"    Pearson syndrome is usually fatal in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/67\">",
"     67",
"    </a>",
"    ]. Those who survive beyond infancy develop signs and symptoms of Kearns-Sayre syndrome. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of the primary mitochondrial disorders can be challenging because of the dual genomic origins (nuclear and mitochondrial), multisystem manifestations, and broad phenotypic heterogeneity encompassed by these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/68\">",
"     68",
"    </a>",
"    ]. The evaluation and diagnostic approach varies according to age, clinical phenotype, and presumed inheritance pattern.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who present with a classic phenotype of one of the maternally inherited syndromes, such as Leber hereditary optic neuropathy, MELAS, MERRF, MIDD, or NARP, initial testing should include appropriate mitochondrial DNA studies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/69\">",
"       69",
"      </a>",
"      ]. When genetic studies are confirmatory, this approach avoids the need for muscle biopsy or an exhaustive metabolic evaluation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Molecular genetic studies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Similarly, for patients who present with a classic picture of a nuclear DNA disorder with an identified gene or linkage, such as autosomal CPEO or MNGIE, initial testing should include molecular genetic studies for the causative nuclear mutation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Molecular genetic studies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For adults with a nonspecific clinical presentation suggestive of a mitochondrial disorder, it is reasonable to begin with a basic laboratory evaluation that includes plasma or cerebrospinal fluid lactate levels, plasma amino acids, plasma acylcarnitines, and urinary organic acids [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/70\">",
"       70",
"      </a>",
"      ]. Given the high prevalence of subclinical muscle or nerve involvement, electromyography is also recommended. An electrocardiogram to rule out fatal arrhythmias should be done. A brain MRI should be considered to look for subclinical leukoencephalopathy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Laboratory studies'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For children with complex neurologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multisystem involvement, the full mitochondrial evaluation outlined below is often necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the major clues to mitochondrial disease is a clear family history of the same disorder, particularly in cases of maternal transmission only. A detailed extended family history is therefore essential. In particular, a history of neonatal or childhood death, deafness, diabetes, cardiac symptoms, visual impairment and developmental delay should be sought.",
"   </p>",
"   <p>",
"    However, up to 62 percent of cases of primary mitochondrial disorders do NOT show maternal transmission. In many of these cases, the mitochondrial phenotype arises from nuclear DNA mutations, and inheritance follows Mendelian genetics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, maternal transmission may not be present even when the phenotype arises from a mitochondrial DNA mutation. This can occur when the mitochondrial mutation is sporadic, or when the mutation load in the mother is below the threshold for clinical symptoms.",
"   </p>",
"   <p>",
"    A major clue to mitochondrial disease is a history of multisystem involvement, particularly in organs most prone to suffer from mitochondrial defects. These include the heart, brain, retina,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skeletal muscle. Additional relevant findings include a history of both neuropathy and myopathy in the same patient.",
"   </p>",
"   <p>",
"    Like other metabolic disorders, mitochondrial myopathies may present during periods of increased body stress, such as a serious illness or",
"    <span class=\"nowrap\">",
"     surgery/anesthesia.",
"    </span>",
"    In addition, they can be associated with prolonged recovery or episodes of rhabdomyolysis out of proportion to the amount of stress.",
"   </p>",
"   <p>",
"    The examination of a patient with suspected mitochondrial disease should look for evidence of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/71\">",
"     71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Optic atrophy and pigmentary retinopathy",
"     </li>",
"     <li>",
"      Cardiac enlargement",
"     </li>",
"     <li>",
"      Central nervous system findings, particularly cerebellar (eg, ataxia), brainstem (eg, ophthalmoparesis, sensorineural hearing loss) and basal ganglia signs (eg, movement disorders)",
"     </li>",
"     <li>",
"      Peripheral nervous system findings, particularly hypotonia (in infants), muscle weakness and peripheral neuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is no consensus, the evaluation of a suspected primary mitochondrial disorder in most cases includes the following tests [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/68,71,72\">",
"     68,71,72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Electrolytes",
"     </li>",
"     <li>",
"      Fasting blood glucose and glycosylated hemoglobin",
"     </li>",
"     <li>",
"      Renal function tests",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Creatine kinase",
"     </li>",
"     <li>",
"      Plasma lactate, pyruvate, and",
"      <span class=\"nowrap\">",
"       lactate/pyruvate",
"      </span>",
"      ratio (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Lactate'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Quantitative plasma amino acids (for elevated alanine)",
"     </li>",
"     <li>",
"      Quantitative urine organic acids (for elevations in Krebs cycle intermediates, methylmalonate, 3-methyl glutaconate, and dicarboxylic acid)",
"     </li>",
"     <li>",
"      Plasma acylcarnitine analysis (for low free",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"       carnitine",
"      </a>",
"      , elevated",
"      <span class=\"nowrap\">",
"       acyl/free",
"      </span>",
"      carnitine ratio, elevations suggestive of disrupted fatty acid oxidation)",
"     </li>",
"     <li>",
"      Electrocardiography",
"     </li>",
"     <li>",
"      Plasma ammonia",
"     </li>",
"     <li>",
"      Brain MRI to evaluate for nonspecific delayed myelination pattern in early disease, symmetric lesions of the deep gray matter specific for Leigh disease, stroke-like lesions suggestive of MELAS, and cerebral",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cerebellar atrophy with bilateral deep gray lesions seen in mitochondrial DNA deletion disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Electromyography and nerve conduction studies even in patients without muscle weakness, sensory symptoms, or areflexia",
"     </li>",
"     <li>",
"      Muscle biopsy (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Muscle biopsy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A plasma creatine kinase level should be checked even though it is usually normal or only slightly elevated. In the context of severe myopathy, a normal plasma creatine kinase level may be a sign of a mitochondrial disease. Preliminary data suggest that the serum level of fibroblast growth factor 21 (FGF21) is significantly elevated in adults and children with mitochondrial respiratory chain disorders, and that elevated FGF21 is a sensitive and specific disease biomarker [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/73\">",
"     73",
"    </a>",
"    ]. While promising, this finding requires confirmation in larger prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the multisystemic nature of several mitochondrial disorders, additional organ-specific testing, as directed by clinical symptoms and signs, is suggested to include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echocardiography for patients with suspected cardiomyopathy",
"     </li>",
"     <li>",
"      Ophthalmologic examination",
"     </li>",
"     <li>",
"      Audiology testing",
"     </li>",
"     <li>",
"      Thyroid function tests",
"     </li>",
"     <li>",
"      Electroencephalography for patients with suspected encephalopathy or seizures",
"     </li>",
"     <li>",
"      Exercise testing for patients with predominant exercise intolerance (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Exercise testing'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Lumbar puncture for patients with neurologic symptoms, to include cerebrospinal fluid analysis of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Routine studies including cell count and differential, glucose, and protein measurement",
"     </li>",
"     <li>",
"      Lactate and pyruvate",
"     </li>",
"     <li>",
"      Quantitative amino acids can be obtained when a glycine or serine metabolism defect, such as nonketotic hyperglycinemia in infants, is suspected",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For pediatric patients with developmental delay, a neurogenetic evaluation is suggested to include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Karyotype",
"     </li>",
"     <li>",
"      Fragile X syndrome testing (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=see_link\">",
"       \"Clinical features and diagnosis of fragile X syndrome in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pediatric neurology consultation",
"     </li>",
"     <li>",
"      Genetics consultation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Lactate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated lactate levels in plasma or cerebrospinal fluid (CSF) can be a supportive feature for the diagnosis of mitochondrial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/68\">",
"     68",
"    </a>",
"    ]. In one study of 100 patients, a single fasting resting plasma lactate concentration of &gt;2.5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    had a sensitivity and specificity of 62 and 100 percent for the diagnosis of primary mitochondrial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/75\">",
"     75",
"    </a>",
"    ]. Despite this finding, many experts believe that lactate levels are nonspecific for mitochondrial disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/68\">",
"     68",
"    </a>",
"    ]. Spurious elevation of plasma lactate can occur due to poor collection or handling methods, and plasma lactate can be physiologically elevated due to secondary mitochondrial dysfunction caused by numerous systemic and metabolic diseases, including thiamine deficiency.",
"   </p>",
"   <p>",
"    CSF lactate measurements are generally more sensitive but less specific, as elevation can occur in a variety of neurologic disorders including stroke or seizure disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to suboptimal specificity, many patients with certain mitochondrial disorders (eg, Leber hereditary optic neuropathy, Leigh syndrome, Kearns-Sayre syndrome, and POLG-associated mitochondrial disorders) consistently have lactate levels that are normal or only minimally elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients with other mitochondrial disorders may have elevated lactate levels only during periods of physiologic stress.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     lactate/pyruvate",
"    </span>",
"    ratio has been proposed as a way to evaluate the redox state of a specific tissue. However, it should be measured only in CSF or tissues such as muscle, since serum levels are not very reliable. The",
"    <span class=\"nowrap\">",
"     lactate/pyruvate",
"    </span>",
"    ratio is probably useful to differentiate pyruvate dehydrogenase deficiency (characterized by an elevated lactic acid level with a normal",
"    <span class=\"nowrap\">",
"     lactate/pyruvate",
"    </span>",
"    ratio) from primary respiratory chain dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise testing can aid the diagnosis of mitochondrial myopathy when the phenotype is nonspecific [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/9\">",
"     9",
"    </a>",
"    ], particularly for patients presenting only with exercise intolerance and fatigue. A reduction in whole body oxygen consumption (VO2max) along with a deficit in peripheral oxygen extraction (A-vO2 difference) using near infrared spectroscopy has a specificity and a sensitivity of up to 75 percent for diagnosing mitochondrial disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/78\">",
"     78",
"    </a>",
"    ]. In a case-control study involving patients with mitochondrial disorders who had relatively mild clinical disease, elevation of plasma lactate level after exercise was supportive of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/79\">",
"     79",
"    </a>",
"    ]. However, the small number of available testing centers limits the clinical usefulness of such testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite advances in molecular genetic analyses, the histologic and histochemical study of the muscle biopsy remains one of the main tools for diagnosing a mitochondrial disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/80\">",
"     80",
"    </a>",
"    ]. Even biopsies of clinically asymptomatic patients can show pathologic abnormalities that are specific for mitochondrial dysfunction.",
"   </p>",
"   <p>",
"    The classic hallmark of mitochondrial diseases is subsarcolemmal and intermyofibrillar accumulation of mitochondria visualized on Gomori trichrome stain. These findings are due to compensatory proliferation of mitochondria, some of them normal and others diseased. The mitochondria appear as bright red masses against the blue background of the myofibers, which led to the term \"ragged red fibers\" (RRF) (",
"    <a class=\"graphic graphic_picture graphicRef62466 \" href=\"UTD.htm?36/47/37624\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A more sensitive way to detect mitochondrial proliferation is to stain them with succinate dehydrogenase (SDH). This complex II enzyme, which is encoded only by nuclear DNA, will almost invariably be increased in mitochondrial disorders. In addition, certain disorders such as MELAS will show \"strongly SDH reactive blood vessels\" or SSVs (",
"    <a class=\"graphic graphic_picture graphicRef82373 \" href=\"UTD.htm?0/21/345\">",
"     picture 2",
"    </a>",
"    ), which indicate mitochondrial proliferation in perivascular smooth muscles and endothelial cells.",
"   </p>",
"   <p>",
"    Another important histochemical reaction for mitochondrial disorders is the cytochrome c oxidase (COX) stain. COX (complex IV) is encoded by both nuclear and mitochondrial DNA. A mosaic pattern of COX-deficient muscle fibers is most suggestive of mitochondrial disorders (",
"    <a class=\"graphic graphic_picture graphicRef82373 \" href=\"UTD.htm?0/21/345\">",
"     picture 2",
"    </a>",
"    ). COX-deficient ragged red fibers usually indicate mitochondrial proliferation in the face of abnormal complex IV function, as often occurs in mitochondrial DNA deletions or transfer RNA mutations. Alternatively, ragged red fibers can be COX-positive with specific point mutations that affect only complex I or III. In the case of nuclear DNA defects in intergenomic signaling or ancillary proteins, we notice diffuse COX-deficient fibers without any ragged red fibers. Finally, the presence of a low proportion of COX-deficient muscle fibers (&lt;2 percent) is nonspecific and could be related to normal aging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electron microscopic study of muscle biopsy generally adds little to the routine histology. The classic picture is paracrystalline inclusions, which are dimeric creatine kinase formations, as well as absent or hypoplastic and dystrophic cristae. These findings are nonspecific and could also be detected in other neuromuscular disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Biochemical analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of respiratory chain function is possible because the individual respiratory chain complexes can be separated by electrophoresis while remaining intact and catalytically active [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The functional analyses of individual respiratory chain complexes are especially useful in diagnosing defects secondary to point mutations or micro-deletions in either mitochondrial DNA or nuclear DNA that affect only one respiratory chain complex. Single complex abnormalities are more commonly seen in children. Testing respiratory complex function requires muscle tissue, and there is no standard method for either performing the analyses or reporting results.",
"   </p>",
"   <p>",
"    Skin fibroblasts have been used successively for biochemical testing in patients with MELAS and MERRF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/83\">",
"     83",
"    </a>",
"    ]. This technique requires culturing the fibroblasts first because the tissue collected after skin biopsy is insufficient by itself. However, the mitochondria collected are often smaller than those in muscle cells and their function may not reflect the function of mitochondria in muscles given the possible different level of heteroplasmy in different tissues. It is therefore not routinely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Molecular genetic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, a specific genetic diagnosis should be pursued even in the presence of a clear-cut clinical picture, as the results can have clinical implications for genetic counseling and might uncover new mutations.",
"   </p>",
"   <p>",
"    When patients present with one of the classic maternally inherited clinical syndromes such as MELAS or MERRF, a genetic analysis of blood and urine for the most common mitochondrial point mutations can be performed by polymerase chain reaction (PCR) of the region of interest and then restriction fragment length polymorphism (RFLP) analysis, sparing the need of a muscle biopsy. Repeat molecular genetic examination using muscle tissue rather than blood or urine is warranted if the initial test is negative. If a point mutation is still not identified using muscle tissue, the entire mitochondrial genome should be sequenced when clinical suspicion of a mitochondrial disorder is high.",
"   </p>",
"   <p>",
"    Most oxidative phosphorylation disorders originate from nuclear DNA abnormalities and are not diagnosed with mitochondrial DNA analysis. In addition, only a limited number of nuclear DNA defects have been identified in mitochondrial disorders, so that genetic diagnoses of many of these disorders have remained elusive. However, almost all new gene discoveries in mitochondrial encephalomyopathies involve nuclear genes encoding either assembly factors or nuclear subunits [",
"    <a class=\"abstract\" href=\"UTD.htm?7/12/7370/abstract/84\">",
"     84",
"    </a>",
"    ]. Nuclear DNA analysis should be performed only if the clinical phenotype and laboratory findings suggest a nuclear DNA disorder with an identified gene or linkage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accumulating evidence suggests that mitochondrial disorders are among the most common inherited metabolic diseases. Muscle is frequently affected, although in some cases the severity is mild or subclinical. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The phenotypic expression of mitochondrial encephalomyopathies is extremely variable. They can present clinically as chronic progressive external ophthalmoplegia or Kearns-Sayre syndrome, as an isolated myopathy, as a severe encephalomyopathy of infancy and childhood, or as a predominantly multisystem disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic progressive external ophthalmoplegia (CPEO) is a slowly progressive disorder characterized by extraocular muscles paresis and bilateral ptosis, usually with onset in the fourth decade. Kearns-Sayre syndrome (KSS) refers to the combination of CPEO with pigmentary retinopathy and onset before age 20. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A genetically heterogeneous group of mitochondrial disorders can occasionally present as an isolated proximal myopathy. Some patients are almost asymptomatic, while others can have fatigue and exercise-induced symptoms including myalgia, myoglobinuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      exercise intolerance. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Isolated myopathy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe encephalomyopathy of infancy or childhood can present in neonates and typically has a poor prognosis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Severe encephalomyopathy of infancy or childhood'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitochondrial disorders that are recognized as clinical syndromes involving multiple organ systems include the following (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Predominantly multisystem disease with myopathy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Barth syndrome (X-linked cardiomyopathy, mitochondrial myopathy and cyclic neutropenia)",
"     </li>",
"     <li>",
"      Growth retardation, amino aciduria, cholestasis, iron overload, lactic acidosis and early death (GRACILE)",
"     </li>",
"     <li>",
"      Leigh syndrome (subacute necrotizing encephalomyelopathy)",
"     </li>",
"     <li>",
"      Maternally inherited deafness and diabetes (MIDD)",
"     </li>",
"     <li>",
"      Mitochondrial encephalopathy with lactic acidosis and stroke-like episodes (MELAS)",
"     </li>",
"     <li>",
"      Mitochondrial neurogastrointestinal encephalopathy (MNGIE)",
"     </li>",
"     <li>",
"      Myoclonic epilepsy with ragged red fibers (MERRF)",
"     </li>",
"     <li>",
"      Neuropathy, ataxia and retinitis pigmentosa (NARP)",
"     </li>",
"     <li>",
"      Pearson syndrome (sideroblastic anemia and pancreatic dysfunction)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of the primary mitochondrial disorders can be challenging because of the dual genomic origins (nuclear and mitochondrial), multisystem manifestations, and broad phenotypic heterogeneity encompassed by these conditions. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with a classic phenotype of one of the maternally inherited syndromes, we suggest initial testing for appropriate mitochondrial DNA studies. Similarly, for patients who present with a classic picture of a nuclear DNA disorder with an identified gene or linkage, we suggest initial molecular genetic studies for the causative nuclear mutation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Molecular genetic studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adults with a nonspecific clinical presentation suggestive of a mitochondrial disorder, we suggest initial laboratory studies that include plasma or cerebrospinal fluid lactate levels, plasma amino acids, plasma acylcarnitines, and urinary organic acids. For children with complex neurologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      multisystem involvement, the full mitochondrial evaluation outlined above is often necessary. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The muscle biopsy remains one of the main tools for diagnosing a mitochondrial disorder. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Muscle biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/1\">",
"      Darin N, Oldfors A, Moslemi AR, et al. The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA anbormalities. Ann Neurol 2001; 49:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/2\">",
"      Garc&iacute;a-Cazorla A, De Lonlay P, Nassogne MC, et al. Long-term follow-up of neonatal mitochondrial cytopathies: a study of 57 patients. Pediatrics 2005; 116:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/3\">",
"      Chinnery PF, Johnson MA, Wardell TM, et al. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000; 48:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/4\">",
"      Elliott HR, Samuels DC, Eden JA, et al. Pathogenic mitochondrial DNA mutations are common in the general population. Am J Hum Genet 2008; 83:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/5\">",
"      Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/6\">",
"      Arpa J, Cruz-Mart&iacute;nez A, Campos Y, et al. Prevalence and progression of mitochondrial diseases: a study of 50 patients. Muscle Nerve 2003; 28:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/7\">",
"      Thorburn DR. Mitochondrial disorders: prevalence, myths and advances. J Inherit Metab Dis 2004; 27:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/8\">",
"      DiMauro S, Hirano M. Mitochondrial encephalomyopathies: an update. Neuromuscul Disord 2005; 15:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/9\">",
"      DiMauro S. Mitochondrial myopathies. Curr Opin Rheumatol 2006; 18:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/10\">",
"      Yu Wai Man CY, Smith T, Chinnery PF, et al. Assessment of visual function in chronic progressive external ophthalmoplegia. Eye (Lond) 2006; 20:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/11\">",
"      Schoser BG, Pongratz D. Extraocular mitochondrial myopathies and their differential diagnoses. Strabismus 2006; 14:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/12\">",
"      Milone M, Massie R. Polymerase gamma 1 mutations: clinical correlations. Neurologist 2010; 16:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/13\">",
"      Milone M, Benarroch EE, Wong LJ. POLG-related disorders: defects of the nuclear and mitochondrial genome interaction. Neurology 2011; 77:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/14\">",
"      Pitceathly RD, Smith C, Fratter C, et al. Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics. Brain 2012; 135:3392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/15\">",
"      Ronchi D, Garone C, Bordoni A, et al. Next-generation sequencing reveals DGUOK mutations in adult patients with mitochondrial DNA multiple deletions. Brain 2012; 135:3404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/16\">",
"      Melberg A, Moslemi AR, Palm O, et al. A patient with two mitochondrial DNA mutations causing PEO and LHON. Eur J Med Genet 2009; 52:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/17\">",
"      Chuenkongkaew WL, Lertrit P, Limwongse C, et al. An unusual family with Leber's hereditary optic neuropathy and facioscapulohumeral muscular dystrophy. Eur J Neurol 2005; 12:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/18\">",
"      Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol 1991; 111:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/19\">",
"      Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010; 10:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/20\">",
"      B&eacute;hin A, Jardel C, Claeys KG, et al. Adult cases of mitochondrial DNA depletion due to TK2 defect: an expanding spectrum. Neurology 2012; 78:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/21\">",
"      Filosto M, Tonin P, Vattemi G, et al. The role of muscle biopsy in investigating isolated muscle pain. Neurology 2007; 68:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/22\">",
"      Gibson K, Halliday JL, Kirby DM, et al. Mitochondrial oxidative phosphorylation disorders presenting in neonates: clinical manifestations and enzymatic and molecular diagnoses. Pediatrics 2008; 122:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/23\">",
"      Rubio-Gozalbo ME, Dijkman KP, van den Heuvel LP, et al. Clinical differences in patients with mitochondriocytopathies due to nuclear versus mitochondrial DNA mutations. Hum Mutat 2000; 15:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/24\">",
"      Skladal D, Sudmeier C, Konstantopoulou V, et al. The clinical spectrum of mitochondrial disease in 75 pediatric patients. Clin Pediatr (Phila) 2003; 42:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/25\">",
"      Labarthe F, Dobbelaere D, Devisme L, et al. Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. J Hepatol 2005; 43:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/26\">",
"      Rahman S, Hargreaves I, Clayton P, Heales S. Neonatal presentation of coenzyme Q10 deficiency. J Pediatr 2001; 139:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/27\">",
"      Cormier-Daire V, Chretien D, Rustin P, et al. Neonatal and delayed-onset liver involvement in disorders of oxidative phosphorylation. J Pediatr 1997; 130:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/28\">",
"      Yaplito-Lee J, Weintraub R, Jamsen K, et al. Cardiac manifestations in oxidative phosphorylation disorders of childhood. J Pediatr 2007; 150:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/29\">",
"      Goldenberg A, Ngoc LH, Thouret MC, et al. Respiratory chain deficiency presenting as congenital nephrotic syndrome. Pediatr Nephrol 2005; 20:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/30\">",
"      G&ouml;tz A, Isohanni P, Pihko H, et al. Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion syndrome. Brain 2008; 131:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/31\">",
"      Alberio S, Mineri R, Tiranti V, Zeviani M. Depletion of mtDNA: syndromes and genes. Mitochondrion 2007; 7:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/32\">",
"      R&ouml;tig A. Renal disease and mitochondrial genetics. J Nephrol 2003; 16:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/33\">",
"      Morris AA, Taylor RW, Birch-Machin MA, et al. Neonatal Fanconi syndrome due to deficiency of complex III of the respiratory chain. Pediatr Nephrol 1995; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/34\">",
"      Artuch R, Salviati L, Jackson S, et al. Coenzyme Q10 deficiencies in neuromuscular diseases. Adv Exp Med Biol 2009; 652:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/35\">",
"      Zeviani M, Peterson P, Servidei S, et al. Benign reversible muscle cytochrome c oxidase deficiency: a second case. Neurology 1987; 37:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/36\">",
"      Horvath R, Kemp JP, Tuppen HA, et al. Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. Brain 2009; 132:3165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/37\">",
"      Wolny S, McFarland R, Chinnery P, Cheetham T. Abnormal growth in mitochondrial disease. Acta Paediatr 2009; 98:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/38\">",
"      Barth PG, Valianpour F, Bowen VM, et al. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am J Med Genet A 2004; 126A:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/39\">",
"      Visap&auml;&auml; I, Fellman V, Vesa J, et al. GRACILE syndrome, a lethal metabolic disorder with iron overload, is caused by a point mutation in BCS1L. Am J Hum Genet 2002; 71:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/40\">",
"      Chinnery PF, Turnbull DM. Epidemiology and treatment of mitochondrial disorders. Am J Med Genet 2001; 106:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/41\">",
"      K&auml;rpp&auml; M, Herva R, Moslemi AR, et al. Spectrum of myopathic findings in 50 patients with the 3243A&gt;G mutation in mitochondrial DNA. Brain 2005; 128:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/42\">",
"      Finsterer J. Leigh and Leigh-like syndrome in children and adults. Pediatr Neurol 2008; 39:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/43\">",
"      Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: clinical features and biochemical and DNA abnormalities. Ann Neurol 1996; 39:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/44\">",
"      Staley KJ, Sims KB, Grant PE, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Case 28-2008. An 8-day-old infant with congenital deafness, lethargy, and hypothermia. N Engl J Med 2008; 359:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/45\">",
"      Pavlakis SG, Phillips PC, DiMauro S, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984; 16:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/46\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 39-1998. A 13-year-old girl with a relapsing-remitting neurologic disorder. N Engl J Med 1998; 339:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/47\">",
"      Montagna P, Gallassi R, Medori R, et al. MELAS syndrome: characteristic migrainous and epileptic features and maternal transmission. Neurology 1988; 38:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/48\">",
"      Ohno K, Isotani E, Hirakawa K. MELAS presenting as migraine complicated by stroke: case report. Neuroradiology 1997; 39:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/49\">",
"      Kaufmann P, Engelstad K, Wei Y, et al. Natural history of MELAS associated with mitochondrial DNA m.3243A&gt;G genotype. Neurology 2011; 77:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/50\">",
"      Hirano M, Ricci E, Koenigsberger MR, et al. Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord 1992; 2:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/51\">",
"      Dimauro S, Tay S, Mancuso M. Mitochondrial encephalomyopathies: diagnostic approach. Ann N Y Acad Sci 2004; 1011:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/52\">",
"      Dickerson BC, Holtzman D, Grant PE, Tian D. Case records of the Massachusetts General Hospital. Case 36-2005. A 61-year-old woman with seizure, disturbed gait, and altered mental status. N Engl J Med 2005; 353:2271.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro S, Hirano M. Myoclonic epilepsy associated with ragged-red fibers. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1520/ (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/54\">",
"      Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 1994; 330:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/55\">",
"      Donovan LE, Severin NE. Maternally inherited diabetes and deafness in a North American kindred: tips for making the diagnosis and review of unique management issues. J Clin Endocrinol Metab 2006; 91:4737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/56\">",
"      Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A&gt;G mitochondrial point mutation. Diabet Med 2008; 25:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/57\">",
"      Guillausseau PJ, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med 2001; 134:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/58\">",
"      Hirano M, Silvestri G, Blake DM, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994; 44:721.",
"     </a>",
"    </li>",
"    <li>",
"     Shoffner JM. Mitochondrial neurogastrointestinal encephalopathy disease. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1179/ (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/60\">",
"      Giordano C, Sebastiani M, De Giorgio R, et al. Gastrointestinal dysmotility in mitochondrial neurogastrointestinal encephalomyopathy is caused by mitochondrial DNA depletion. Am J Pathol 2008; 173:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/61\">",
"      Nishino I, Spinazzola A, Papadimitriou A, et al. Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000; 47:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/62\">",
"      Teitelbaum JE, Berde CB, Nurko S, et al. Diagnosis and management of MNGIE syndrome in children: case report and review of the literature. J Pediatr Gastroenterol Nutr 2002; 35:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/63\">",
"      Shaibani A, Shchelochkov OA, Zhang S, et al. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol 2009; 66:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/64\">",
"      Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/65\">",
"      Uziel G, Moroni I, Lamantea E, et al. Mitochondrial disease associated with the T8993G mutation of the mitochondrial ATPase 6 gene: a clinical, biochemical, and molecular study in six families. J Neurol Neurosurg Psychiatry 1997; 63:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/66\">",
"      White SL, Collins VR, Wolfe R, et al. Genetic counseling and prenatal diagnosis for the mitochondrial DNA mutations at nucleotide 8993. Am J Hum Genet 1999; 65:474.",
"     </a>",
"    </li>",
"    <li>",
"     DiMauro S, Hirano M. Mitochondrial DNA deletion syndromes. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1203/ (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/68\">",
"      Mitochondrial Medicine Society's Committee on Diagnosis, Haas RH, Parikh S, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008; 94:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/69\">",
"      Taylor RW, Schaefer AM, Barron MJ, et al. The diagnosis of mitochondrial muscle disease. Neuromuscul Disord 2004; 14:237.",
"     </a>",
"    </li>",
"    <li>",
"     Chinnery PF. Mitochondrial disorders overview. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1224/ (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/71\">",
"      McFarland R, Taylor RW, Turnbull DM. The neurology of mitochondrial DNA disease. Lancet Neurol 2002; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/72\">",
"      Haas RH, Parikh S, Falk MJ, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007; 120:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/73\">",
"      Suomalainen A, Elo JM, Pietil&auml;inen KH, et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011; 10:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/74\">",
"      Turnbull D. A new biomarker for mitochondrial disease. Lancet Neurol 2011; 10:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/75\">",
"      Tarnopolsky M, Stevens L, MacDonald JR, et al. Diagnostic utility of a modified forearm ischemic exercise test and technical issues relevant to exercise testing. Muscle Nerve 2003; 27:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/76\">",
"      Jackson MJ, Schaefer JA, Johnson MA, et al. Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. Brain 1995; 118 ( Pt 2):339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/77\">",
"      Robinson BH. Cell culture studies on patients with mitochondrial diseases: molecular defects in pyruvate dehydrogenase. J Bioenerg Biomembr 1988; 20:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/78\">",
"      Tarnopolsky MA, Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports Exerc 2005; 37:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/79\">",
"      Lindholm H, L&ouml;fberg M, Somer H, et al. Abnormal blood lactate accumulation after exercise in patients with multiple mitochondrial DNA deletions and minor muscular symptoms. Clin Physiol Funct Imaging 2004; 24:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/80\">",
"      Sarnat HB, Mar&iacute;n-Garc&iacute;a J. Pathology of mitochondrial encephalomyopathies. Can J Neurol Sci 2005; 32:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/81\">",
"      Barron MJ, Chinnery PF, Howel D, et al. Cytochrome c oxidase deficient muscle fibres: substantial variation in their proportions within skeletal muscles from patients with mitochondrial myopathy. Neuromuscul Disord 2005; 15:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/82\">",
"      Debray FG, Lambert M, Mitchell GA. Disorders of mitochondrial function. Curr Opin Pediatr 2008; 20:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/83\">",
"      James AM, Wei YH, Pang CY, Murphy MP. Altered mitochondrial function in fibroblasts containing MELAS or MERRF mitochondrial DNA mutations. Biochem J 1996; 318 ( Pt 2):401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/12/7370/abstract/84\">",
"      Tucker EJ, Compton AG, Thorburn DR. Recent advances in the genetics of mitochondrial encephalopathies. Curr Neurol Neurosci Rep 2010; 10:277.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5151 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7370=[""].join("\n");
var outline_f7_12_7370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H124912918\">",
"      Leber hereditary optic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Isolated myopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Severe encephalomyopathy of infancy or childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Predominantly multisystem disease with myopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Leigh syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - MELAS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - MERRF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MIDD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - MNGIE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - NARP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Pearson syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Lactate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Biochemical analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Molecular genetic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5151\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5151|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/47/37624\" title=\"picture 1\">",
"      Ragged red fibers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/21/345\" title=\"picture 2\">",
"      Muscle histochemistry mitochondrial disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5151|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/14/16621\" title=\"table 1\">",
"      Genetics of mitochondrial myopathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/4/34889?source=related_link\">",
"      Clinical features and diagnosis of fragile X syndrome in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/30/2536?source=related_link\">",
"      Mitochondrial myopathies: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12853?source=related_link\">",
"      Mitochondrial structure, function, and genetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4520?source=related_link\">",
"      Renal involvement in the mitochondrial cytopathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_12_7371="TCA levels adol depression";
var content_f7_12_7371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Therapeutic monitoring of cyclic antidepressant concentrations in adolescent depression",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication (metabolite)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Therapeutic range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Threshold for toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Amitriptyline (Nortriptyline)",
"       </td>",
"       <td>",
"        120 - 250 ng/mL",
"       </td>",
"       <td>",
"        &gt;500 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50 - 150 mg/mL",
"       </td>",
"       <td>",
"        &gt;500 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Imiparmine (Desipramine)",
"       </td>",
"       <td>",
"        100 - 300 ng/mL",
"       </td>",
"       <td>",
"        &gt;500 ng/mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        75 - 300 ng/mL",
"       </td>",
"       <td>",
"        &gt;500 ng/mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7371=[""].join("\n");
var outline_f7_12_7371=null;
var title_f7_12_7372="Sources of vitamin D PI";
var content_f7_12_7372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected food sources of vitamin D",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        International units per serving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cod liver oil, 1 tablespoon",
"       </td>",
"       <td>",
"        1360",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salmon (sockeye), cooked, 3 ounces",
"       </td>",
"       <td>",
"        794",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mushrooms that have been exposed to ultraviolet light to increase vitamin D, 3 ounces (not yet commonly available)",
"       </td>",
"       <td>",
"        400",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mackerel, cooked, 3 ounces",
"       </td>",
"       <td>",
"        388",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tuna fish, canned in water, drained, 3 ounces",
"       </td>",
"       <td>",
"        154",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milk, nonfat, reduced fat, and whole, vitamin D-fortified, 1 cup",
"       </td>",
"       <td>",
"        115 to 124",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orange juice fortified with vitamin D, 1 cup (check product labels, as amount of added vitamin D varies)",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yogurt, fortified with 20 percent of the DV for vitamin D, 6 ounces (more heavily fortified yogurts provide more of the DV)",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Margarine, fortified, 1 tablespoon",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sardines, canned in oil, drained, 2 sardines",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver, beef, cooked, 3.5 ounces",
"       </td>",
"       <td>",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ready-to-eat cereal, fortified with 10 percent of the DV for vitamin D, 0.75-1 cup (more heavily fortified cereals might provide more of the DV)",
"       </td>",
"       <td>",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Egg, 1 whole (vitamin D is found in yolk)",
"       </td>",
"       <td>",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cheese, Swiss, 1 ounce",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     US Department of Agriculture, Agricultural Research Service. USDA Nutrient Database for Standard Reference, Release 22, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7372=[""].join("\n");
var outline_f7_12_7372=null;
var title_f7_12_7373="Rx crypto mening HIV";
var content_f7_12_7373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antifungal treatment recommendations for cryptococcal meningoencephalitis in human immunodeficiency virus-infected individuals (adult dosing)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Regimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Induction therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amphotericin B conventional (0.7 to 1 mg/kg per day IV)",
"        <strong>",
"         plus",
"        </strong>",
"        flucytosine (100 mg/kg per day orally in four divided doses)*",
"       </td>",
"       <td class=\"sublist_other\">",
"        Two&nbsp;weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patients with renal function concerns: See recommendations in the text",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Patients intolerant of flucytosine: Amphotericin B conventional (0.7 to 1 mg/kg per day IV) or liposomal amphotericin B (3 to 4 mg/kg per day IV) or amphotericin B lipid complex (5 mg/kg per day IV)",
"       </td>",
"       <td class=\"sublist_other\">",
"        Four to six&nbsp;weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Alternatives for induction therapy",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amphotericin B conventional plus fluconazole",
"       </td>",
"       <td class=\"sublist_other\">",
"        ...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluconazole plus flucytosine",
"       </td>",
"       <td class=\"sublist_other\">",
"        ...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fluconazole",
"       </td>",
"       <td class=\"sublist_other\">",
"        ...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Itraconazole",
"       </td>",
"       <td class=\"sublist_other\">",
"        ...",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consolidation therapy: fluconazole 400 mg (6 mg/kg) per day orally",
"       </td>",
"       <td>",
"        Eight&nbsp;weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintenance therapy: fluconazole 200 mg per day orally*",
"       </td>",
"       <td>",
"        &ge;1 year",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Alternatives for maintenance therapy",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Itraconazole 200 mg twice per day orally (monitor serum drug levels)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;1 year",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Amphotericin B conventional 1 mg/kg per week IV",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"sublist_other\">",
"        &ge;1 year",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Amphotericin B conventional: amphotericin B desoxycholate; HAART: highly active antiretroviral therapy; IRIS: immune reconstitution inflammatory syndrome;&nbsp;IV: intravenous.",
"     <br>",
"      * We generally do not begin antiretroviral medications within the first two weeks of induction antifungal therapy; we subsequently initiate&nbsp;antiretroviral therapy&nbsp;within four to eight weeks after the induction phase has been completed since most cases of IRIS occur before this time period.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       In unique clinical situations in which primary recommendations are not available, consideration of alternative regimens may be made - but not encouraged - as substitutes. See text for dosages.",
"       <br>",
"        &Delta; With successful introduction of HAART, a CD4 cell count &ge;100 cells/microL, and low or nondetectable viral load for &ge;3 months with minimum of&nbsp;one year of antifungal therapy.",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         Inferior to the primary recommendation.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Perfect JR, Disnukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291. Copyright &copy; Infectious Diseases Society of America.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7373=[""].join("\n");
var outline_f7_12_7373=null;
var title_f7_12_7374="Placental weight";
var content_f7_12_7374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72177&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Placental weight standards",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"3\">",
"        Gestational age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Singleton",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"5\">",
"        Twin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Percentiles",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Percentiles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        10",
"       </td>",
"       <td class=\"subtitle3\">",
"        25",
"       </td>",
"       <td class=\"subtitle3\">",
"        50",
"       </td>",
"       <td class=\"subtitle3\">",
"        75",
"       </td>",
"       <td class=\"subtitle3\">",
"        90",
"       </td>",
"       <td class=\"subtitle3\">",
"        10",
"       </td>",
"       <td class=\"subtitle3\">",
"        25",
"       </td>",
"       <td class=\"subtitle3\">",
"        50",
"       </td>",
"       <td class=\"subtitle3\">",
"        75",
"       </td>",
"       <td class=\"subtitle3\">",
"        90",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        56",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        110",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        137.8",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        190",
"       </td>",
"       <td>",
"        218",
"       </td>",
"       <td>",
"        245",
"       </td>",
"       <td>",
"        270",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        138",
"       </td>",
"       <td>",
"        157",
"       </td>",
"       <td>",
"        176",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        191",
"       </td>",
"       <td>",
"        219",
"       </td>",
"       <td>",
"        251",
"       </td>",
"       <td>",
"        282",
"       </td>",
"       <td>",
"        310",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        145",
"       </td>",
"       <td>",
"        166",
"       </td>",
"       <td>",
"        189",
"       </td>",
"       <td>",
"        212",
"       </td>",
"       <td>",
"        233",
"       </td>",
"       <td>",
"        232",
"       </td>",
"       <td>",
"        267",
"       </td>",
"       <td>",
"        307",
"       </td>",
"       <td>",
"        346",
"       </td>",
"       <td>",
"        382",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        175",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        227",
"       </td>",
"       <td>",
"        255",
"       </td>",
"       <td>",
"        280",
"       </td>",
"       <td>",
"        284",
"       </td>",
"       <td>",
"        330",
"       </td>",
"       <td>",
"        380",
"       </td>",
"       <td>",
"        430",
"       </td>",
"       <td>",
"        475",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        210",
"       </td>",
"       <td>",
"        238",
"       </td>",
"       <td>",
"        270",
"       </td>",
"       <td>",
"        302",
"       </td>",
"       <td>",
"        331",
"       </td>",
"       <td>",
"        345",
"       </td>",
"       <td>",
"        401",
"       </td>",
"       <td>",
"        464",
"       </td>",
"       <td>",
"        527",
"       </td>",
"       <td>",
"        584",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        249",
"       </td>",
"       <td>",
"        281",
"       </td>",
"       <td>",
"        316",
"       </td>",
"       <td>",
"        352",
"       </td>",
"       <td>",
"        384",
"       </td>",
"       <td>",
"        409",
"       </td>",
"       <td>",
"        478",
"       </td>",
"       <td>",
"        554",
"       </td>",
"       <td>",
"        631",
"       </td>",
"       <td>",
"        700",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        290",
"       </td>",
"       <td>",
"        325",
"       </td>",
"       <td>",
"        364",
"       </td>",
"       <td>",
"        403",
"       </td>",
"       <td>",
"        438",
"       </td>",
"       <td>",
"        472",
"       </td>",
"       <td>",
"        554",
"       </td>",
"       <td>",
"        644",
"       </td>",
"       <td>",
"        734",
"       </td>",
"       <td>",
"        815",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        331",
"       </td>",
"       <td>",
"        369",
"       </td>",
"       <td>",
"        411",
"       </td>",
"       <td>",
"        453",
"       </td>",
"       <td>",
"        491",
"       </td>",
"       <td>",
"        531",
"       </td>",
"       <td>",
"        624",
"       </td>",
"       <td>",
"        727",
"       </td>",
"       <td>",
"        830",
"       </td>",
"       <td>",
"        923",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        372",
"       </td>",
"       <td>",
"        412",
"       </td>",
"       <td>",
"        457",
"       </td>",
"       <td>",
"        501",
"       </td>",
"       <td>",
"        542",
"       </td>",
"       <td>",
"        582",
"       </td>",
"       <td>",
"        684",
"       </td>",
"       <td>",
"        798",
"       </td>",
"       <td>",
"        912",
"       </td>",
"       <td>",
"        1014",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        409",
"       </td>",
"       <td>",
"        452",
"       </td>",
"       <td>",
"        499",
"       </td>",
"       <td>",
"        547",
"       </td>",
"       <td>",
"        589",
"       </td>",
"       <td>",
"        619",
"       </td>",
"       <td>",
"        728",
"       </td>",
"       <td>",
"        850",
"       </td>",
"       <td>",
"        972",
"       </td>",
"       <td>",
"        1082",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        442",
"       </td>",
"       <td>",
"        487",
"       </td>",
"       <td>",
"        537",
"       </td>",
"       <td>",
"        587",
"       </td>",
"       <td>",
"        632",
"       </td>",
"       <td>",
"        638",
"       </td>",
"       <td>",
"        753",
"       </td>",
"       <td>",
"        879",
"       </td>",
"       <td>",
"        1005",
"       </td>",
"       <td>",
"        1118",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Pinar, H, Sung, J, Oyer, CE, Singer, DB. Reference values for singleton and twin placental weights. Pediatr Pathol Lab Med 1996; 16:901.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7374=[""].join("\n");
var outline_f7_12_7374=null;
var title_f7_12_7375="Cavoatrial tumor thrombus";
var content_f7_12_7375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavoatrial tumor thrombus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four stages of cavoatrial tumor extension are depicted. In type I and II disease, tumor excision can be safely achieved by means of simple proximal and distal control of the IVC, while for type III and IV disease, exposure and isolation of the IVC is more extensive, requiring liver mobilization with or without the use of cardiopulmonary bypass and, in some circumstances, deep hypothermic circulatory arrest.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chiappini, B, Savini, C, Marinelli, G, et al. Cavoatrial tumor thrombus: Single-stage surgical approach with profound hypothermia and circulatory arrest, including a review of the literature. J Thor Cardiovasc Surg 2002; 124:684. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_12_7375=[""].join("\n");
var outline_f7_12_7375=null;
